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 Abstract 
Background and aim: Coronary heart disease (CHD), the most common form of which is myocardial 
infarction (MI), is a significant health problem. In Sweden circulatory diseases account for 50% of total 
mortality; half of these are associated with CHD. The percentage of foreign-born in Sweden is about 16 
% of the total population. Ethnic differences in disease and its outcomes have been widely reported 
internationally. This thesis was to increase understanding of the differences in utilization of health care 
by exploring the incidence and recurrence of MI, drug consumption after MI, prognosis after MI and 
coronary artery bypass graft (CABG) in relation to country of birth, socio-economic position (SEP) and 
gender.  
Materials and methods: The data used in this thesis are from newly established Migration and Health 
Cohort specifically designed to address health status among immigrants in Sweden. The cohort is a 
linkage of several national registers. There were four studies. The study periods were 1987–2008 (Study 
I), 2006–2008 (Study II), 1987–2007 (Study III) and 1995 – 2007 (Study IV). The study populations 
were the total Swedish population (Study I), all first MI patients (Studies I, II and III) and all individuals 
who underwent a first isolated CABG (Study IV). The outcomes were incidence of and mortality after 
MI (Study I), drug use after MI (Study II), recurrent MI (Study III) and mortality after CABG 
respectively (Study IV). The potential confounders were age, sex, education, comorbidities, calendar 
years of follow-up, marital status and waiting time for surgery. We calculated incidence rate ratios 
(IRRs) and hazard ratios (HRs) (Studies I, III and IV) and odds ratios (ORs) (Study II) with 95% 
confidence intervals (CIs) in multivariable adjusted models using Poisson, Cox, and logistic regression 
models, respectively. 
Results: We observed downward trends in first-time MI incidence and case fatality after day 28 for both 
sexes regardless of country of birth. The trends were, however, less pronounced among female and 
foreign-born subjects. Among those who did not used cardiovascular drugs before MI, we found no 
difference in drug use after MI by migration status in an adjusted model (OR 1.00, 95 % CI 0.89–1.12). 
Among those  who used some but not all recommended cardiovascular drugs before MI, foreign-born 
cases had a non-significant slightly lower use of recommended drugs in the adjusted model (OR 0.92, 95 
% CI 0.83–1.03). Among those with the lowest education level, foreign-born patients had a slightly 
lower use of recommended drug compared to Sweden-born patients. Women with a low SEP used fewer 
drugs after MI irrespective of country of birth (Study II). A downward trend in risk of second MI was 
found. However, regardless of country of birth, men had a higher risk of second MI than women (HR 
1.14, 95% CI 1.12–1.55). Foreign-born men and women had a slightly increased HR than their Sweden-
born counterparts. Foreign-born patients who had lived in Sweden for less than 35 years had a higher 
risk than those who had lived there for 35 years or longer (Study III). There was no significant difference 
in overall early or late mortality after CABG between foreign-born and Sweden-born patients in both 
sexes. However, all-cause mortality differed between some countries and was highest in foreign-born 
men from Eastern Africa (HR 3.80, 95% CI 1.58–9.17), China (HR 3.61, 95% CI 1.50–8.69) and Chile 
(HR 2.12, 95% CI 1.01–4.47) (Study IV). Patients with a low level of education had higher incidence of 
MI and worse prognosis after MI and CABG compared to those with longer than 12 years of education 
irrespective of sex and country of birth (Studies I, III and IV). This difference was more pronounced 
among foreign-born women.  
Conclusion: A slightly increased incidence of and mortality after first MI, and risk of recurrent MI was 
found among foreign-born compared to Sweden-born individuals. Although the incidence of and 
mortality after first-time MI, and risk of recurrent MI, continued to decrease over time, low SEP, 
measured in terms of education level, independent of country of birth and sex, remained an important 
risk indicator for these events. There were no apparent differences in drug prescription after MI between 
foreign-born and Sweden-born patients. There were no differences in early and late mortality after 
isolated CABG. However, there was inequity in adequate secondary prevention therapy after MI 
between education groups regardless of country of birth. 
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 ABSTRACT 
Background and aim: Coronary heart disease (CHD), the most common form 
of which is myocardial infarction (MI), is a significant health problem. In 
Sweden circulatory diseases account for 50% of total mortality; half of these are 
associated with CHD. The percentage of foreign-born in Sweden is about 16 % 
of the total population. Ethnic differences in disease and its outcomes have been 
widely reported internationally. This thesis was to increase understanding of the 
differences in utilization of health care by exploring the incidence and recurrence 
of MI, drug consumption after MI, prognosis after MI and coronary artery 
bypass graft (CABG) in relation to country of birth, socio-economic position 
(SEP) and gender.  
Materials and methods: The data used in this thesis are from newly established 
Migration and Health Cohort specifically designed to address health status 
among immigrants in Sweden. The cohort is a linkage of several national 
registers. There were four studies. The study periods were 1987–2008 (Study I), 
2006–2008 (Study II), 1987–2007 (Study III) and 1995 – 2007 (Study IV). The 
study populations were the total Swedish population (Study I), all first MI 
patients (Studies I, II and III) and all individuals who underwent a first isolated 
CABG (Study IV). The outcomes were incidence of and mortality after MI 
(Study I), drug use after MI (Study II), recurrent MI (Study III) and mortality 
after CABG respectively (Study IV). The potential confounders were age, sex, 
education, comorbidities, calendar years of follow-up, marital status and waiting 
time for surgery. We calculated incidence rate ratios (IRRs) and hazard ratios 
(HRs) (Studies I, III and IV) and odds ratios (ORs) (Study II) with 95% 
confidence intervals (CIs) in multivariable adjusted models using Poisson, Cox, 
and logistic regression models, respectively. 
Results: We observed downward trends in first-time MI incidence and case 
fatality after day 28 for both sexes regardless of country of birth. The trends 
were, however, less pronounced among female and foreign-born subjects. 
Among those who did not used cardiovascular drugs before MI, we found no 
difference in drug use after MI by migration status in an adjusted model (OR 
1.00, 95 % CI 0.89–1.12). Among those who used some but not all 
recommended cardiovascular drugs before MI, foreign-born cases had a non-
significant slightly lower use of recommended drugs in the adjusted model (OR 
0.92, 95 % CI 0.83–1.03). Among those with the lowest education level, foreign-
born patients had a slightly lower use of recommended drug compared to 
Sweden-born patients. Women with a low SEP used fewer drugs after MI 
irrespective of country of birth (Study II). A downward trend in risk of second 
MI was found. However, regardless of country of birth, men had a higher risk of 
second MI than women (HR 1.14, 95% CI 1.12–1.55). Foreign-born men and 
women had a slightly increased HR than their Sweden-born counterparts. 
Foreign-born patients who had lived in Sweden for less than 35 years had a 
higher risk than those who had lived there for 35 years or longer (Study III). 
There was no significant difference in overall early or late mortality after CABG 
between foreign-born and Sweden-born patients in both sexes. However, all-
cause mortality differed between some countries and was highest in foreign-born 
men from Eastern Africa (HR 3.80, 95% CI 1.58–9.17), China (HR 3.61, 95% 
CI 1.50–8.69) and Chile (HR 2.12, 95% CI 1.01–4.47) (Study IV). Patients with 
a low level of education had higher incidence of MI and worse prognosis after 
MI and CABG compared to those with longer than 12 years of education 
irrespective of sex and country of birth (Studies I, III and IV). This difference 
was more pronounced among foreign-born women.  
Conclusion: A slightly increased incidence of and mortality after first MI, and 
risk of recurrent MI was found among foreign-born compared to Sweden-born 
individuals. Although the incidence of and mortality after first-time MI, and risk 
of recurrent MI, continued to decrease over time, low SEP, measured in terms of 
education level, independent of country of birth and sex, remained an important 
risk indicator for these events. There were no apparent differences in drug 
prescription after MI between foreign-born and Sweden-born patients. There 
were no differences in early and late mortality after isolated CABG. However, 
there was inequity in adequate secondary prevention therapy after MI between 
education groups regardless of country of birth. 
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1 INTRODUCTION 
Coronary heart disease (CHD), the most common form of which is 
myocardial infarction (MI), is the main component of cardiovascular disease 
(CVD).  CVD is a universal public health problem and considered to be a major 
cause of deaths worldwide. In 2008, of a total of 17.3 million cardiovascular 
deaths, 7.3 million were due to heart attacks. CVD accounts for more than 4 
million deaths in Europe each year, or which 1.8 million are due to CHD (1-3). 
CHD remains the leading cause of death in high- and middle income countries 
and is predicted to be the leading cause worldwide within a few decades (4). In 
Sweden, CVD is the most common cause of death in both sexes. The burden of 
CVD is an important issue in Sweden. In 2010, CVD was the primary cause of 
death in 40% of cases, and CHD accounted for 42% of cardiovascular deaths (5, 
6). 
The rise in international migration has made the subject of health among 
immigrants increasingly important worldwide. In Sweden about 16 % of the 
population, approximately 1.5 million individuals, are born outside Sweden (7). 
Depending on ethnicity (8-13), socioeconomic position (SEP) (14-19), and sex 
(20, 21), there are  differences in the incidence, morbidity, prognosis and 
mortality after MI. There are some indications that access to health care services 
and health care utilization is influenced by country of birth, SEP, and sex (10, 
13, 22-28). Ethnic differences in health care have been widely reported 
internationally. Whites seem more likely than other ethnic groups to undergo 
cardiovascular procedures such as angiography, angioplasty and coronary artery 
bypass graft (CABG) after MI in the United States (13, 23). Studies exploring 
access to health care including interventional services for MI patients are 
important. Prescribed drugs, surgical interventions, re-occurrence of disease, 
survival are a few examples of measures that can be assessed to compare 
differences in access to and consumption of health care among different 
populations. 
 2 
2 BACKGROUND 
2.1 IMMIGRATION TO SWEDEN 
The pattern of emigration from and immigration to Sweden has changed 
dramatically over the past decades. Sweden  had a net emigration during 1930s 
and World War I  but become a country of net immigration since the World War 
II  (29).  
The total population of Sweden as of 31 December 2013 was 9,644, 864 of 
which 1, 533, 493 (15.9%) were born outside Sweden (7) (men: 748, 366 and 
women: 785, 127) (30). Currently, about one-fifth (20.7 %) of Sweden's 
population has a so called  immigrant background  (born outside Sweden or born 
in Sweden with one or both parents born outside of Sweden) (7). 
2.1.1 Trends in immigration to Sweden 
There are various reasons for immigration to a new country including labour, 
social, religious and political motivation. There has been a rising flow of 
immigration to Sweden since 1960 (Figure1 and figure 2). Foreign-born 
individuals comprised 11.3 % of the total Swedish population in 2000, up from 
9.2 % in 1990, 7.5 % in 1980 and 4.0 % in 1960 (7). After the World War II, 
Sweden as an industrialized country actively began to recruit foreign labour, 
mainly from Finland, Germany, Greece, Italy, and the former Yugoslavia (29, 
31). After the 1970s, immigrants have predominantly originated from non-
Nordic countries, and were typically refugees seeking asylum on humanitarian 
grounds. Immigration waves to Sweden were from Uganda after 4 August 1972, 
from Chile following the revolution against President Salvador Allende in 1973, 
from Iraq and Iran in the 1980, and from the former Yugoslavia in the 1990 (31, 
32). In the last two decades there has been a large inflow of immigrant to 
Sweden, both refugees and labour immigrants. Recently Sweden has offered 
resident permits to personns from the Middle East on humanitarian ground as 
demonstrated by its acceptance of refugees from the civil war in Syria. In 2013, 
the number of foreign-born residents from the Syrian Arab Republic was 41,748; 
this is more than twice the number of 19, 646 in 2009 (30).  
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Figure 1: Swedish population in the years 1987-2007 by migration status 
(Sweden-born and foreign-born individuals) (Source: Statistics Sweden) 
 
 
Figure 2: Foreign-born population in Sweden in the years 1960–2013 (Source: 
Statistics Sweden) 
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In 2013, the five leading countries of origin for immigrants to Sweden were 
Finland, Iraq, Poland, the former Yugoslavia and Iran (30) (Table 1). 
 
Table 1: Number of foreign-born individuals in Sweden by country of birth in 
2013 
Country of birth Number of foreign-
born individuals 
Percentage based 
on total 
population  
Percentage based 
on immigrant 
population 
Finland 161,129 1.67 10.5  
Iraq 128,946 1.33 8.4 
Poland 78,175 0.81 5.9 
Former Yugoslavia 68,554 0.71 4.47 
Iran 67,211 0.69 4.38 
Bosnia and Herzegovina 56,804 0.58 3.70 
Somalia 54,221 0.56 3.53 
Germany 48,987 0.50 3.19 
Turkey 45,676 0.47 2.97 
Denmark 43,198 0.44 2.81 
(Source: Statistics Sweden) 
 
2.2 MIGRATION AND HEALTH 
The multi-ethnic nature of the world population seems to be increasing due 
to globalization, travel, business, study and migration. An estimated 214 million 
international migrants and almost 0.75 billion people with internal migration are 
reported worldwide (33-35). Such a large degree of migration demands polices at 
both global and local levels to optimize resources for a better quality of life for 
all human beings. Recently, the effect of migration on health has become an 
important issue. At the beginning of the last century, the focus of health issues 
among immigrants was more on controlling communicable diseases in order to 
prevent the spread of the disease within the host population. Whereas nowadays 
the discussion on migration and health is more directed towards a human rights-
based perspective i.e. “a healthy life for all”. Exploring the issue of migration 
and health is not only important because of the threat to society and to public 
health in the host country, but also in order to provide the same service to 
immigrants as to the host population (36, 37). The issue of migration and health 
has been described worldwide. In countries such as the United States and United 
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Kingdom with a long history of immigration, the disparities in health status 
among minorities have been widely reported (38, 39). Studies on health 
distribution between foreign-born individuals and the host population showed 
poorer health for Finnish people in Sweden (40, 41), and worse health outcomes 
among Irish and Scottish immigrants in England (42-44). 
 The findings of studies of the effect of immigration on health outcomes have 
been contradictory. Some studies have shown poorer health among immigrants 
compared to the host population. The largest immigrant group in Sweden is from 
Finland and an increased mortality risk for Finnish men and women has been 
found. In addition a higher risk of CHD mortality for women born in Finland and 
Eastern Europe has been reported (10, 11). However, others have shown 
opposite findings. Foreign-born individuals have been shown to have better 
health compared to the host population; for example lower mortality rates have 
been reported among black and Hispanic immigrants compared with US- 
counterparts, and foreign-born blacks have been shown to have the longest life-
expectancy (45-48). The different health status among foreign-born groups 
compared to the host population may be due to differences in lifestyles, and in 
preventive or risky health behaviors (49). However there is a lack of 
comprehensive evidence to determine the true explanation for poorer or better 
health among the immigrant compared to the host population of a country. Many 
factors may explain this variation in health. It may depend on culture-based 
lifestyles, habits and norms; if these are unfavorable in the country of origin, 
immigrants will have a poorer risk profile than the host population (49). 
Furthermore, migration can be a stressful process, with increased anxiety, 
sleeping problems and stress. These factors may have a negative impact on 
psychological health, and may result in depression, anxiety and tension, and also 
post-traumatic stress disorder (50, 51). It is very difficult to clearly state whether 
migration is good or bad for individual health; this depends on the general state 
of the society and both population and individual health in the country of origin, 
as well as the general state of society and population health in host country.  
Also, immigrants health depends on immigrants’ origin from high-income 
countries, and those  or low-income countries, and on which individuals in these 
settings are more likely to emigrate (52). Is it the relatively sick and poor who 
emigrate, or the relatively rich and healthy who take their chances of an even 
better life somewhere else? However, emigration from countries of war is 
usually not voluntary and may be due to a forced choice which may have a 
negative impact on health among immigrants (53).  
However, immigrants have also been shown to be healthier than persons of the 
same individual characteristics in the host country. The common explanation is 
the “healthy migrant effect” which has a positive selective effect on immigrant 
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health (46, 54, 55). In fact, there is an indication that immigrants also have better 
levels of health than the population in their country of origin, in particular young 
immigrants (55-57). It seems that  the “healthy migrant effect” is stronger for 
immigrants coming from low income countries than from high income countries 
(58). This could reflect the fact that emigrants from low-income countries more 
often are those who already have resources and capabilities that can make 
emigration possible. On the other hand, persons with resources and capabilities 
in high-income countries might be satisfied with their life, whereas those without 
such resources and capabilities are more eager to emigrate. In general, this health 
advantage has been found to deteriorate (59, 60). Many factors can explain this 
advantage in health: a stronger social status and support network from the home 
country primarily provides a positive influence and exerts a protective effect on 
immigrants’ health in the early years of immigration; but these factors are 
gradually lost as foreign-born individuals undergo a process of assimilation (61). 
Also, a less risky lifestyle with better diet and less tobacco smoking and a lower 
rate of excessive alcohol consumption may play a role. However other studies 
have found a health disadvantage among immigrants. The longer the foreign-
born individual has lived in a host country the better was the health outcome. For 
example, in a study of Finnish immigrants in Sweden, the risk of MI was found 
to be higher compared to those born in Sweden. However, the relative risk of 
CHD decreased with duration of stay in Sweden. The mechanism of reducing 
risk of developing MI for men born in Finland in relation to duration of stay in 
Sweden is unknown (8). The authors of the study explained that the difference in 
relative risk of developing MI between Finland and Sweden is mainly due to 
environmental factors (8).  
Migration itself is a complex and dynamic phenomenon with different related 
causes such as family ties, professional, economic and educational reasons and 
refugee. The psychobiological impact of forced migration, such as separation 
from friends and relatives, different language and culture, loss of contact with 
own ethnic group and loss of social status, may add to these mechanisms behind 
migration and health (38). Another issue related to migration and health is access 
to medical services. Some foreign-born individuals are unfamiliar with how to 
access services in the host country in an effective way and may face difficulties 
in contact with the healthcare services because of language barriers (62). These 
above are all recognized as underlying factors and have impact on inequities 
regarding migration and health. 
     
 
  7 
2.3 SOCIOECONOMIC POSITION  
Social inequalities in health are present worldwide as shown by the 
contemporary World Health Organization (WHO) report (63). In social 
epidemiology, different terminology has been used to describe social 
stratification in society, for example SEP, socioeconomic status, and social class. 
Indicators of SEP, for example occupation, education or income and wealth, or 
combinations thereof,  have been used interchangeably (64). The following (i.e. 
Occupation-based, Wealth, income and education): are most common 
measures used in epidemiology.  
Occupation-based has been commonly used as an indicator of SEP in some 
countries especially in Europe. For example the use of this variable is 
particularly popular in the United Kingdom (65), Sweden, Norway, Denmark 
and Finland. Occupation is strongly related to income; information about 
occupation may provide an indication of the individual level of income and 
reflect the social status associated with a variety of occupations. 
Income  another commonly used indicator of SEP, may indicate the ability of the 
individual to spend money on obtaining a good quality of life in terms of 
housing, place of work, food, lifestyle, sports and recreation. Income can also in 
some settings be an important means for the individual to access high-quality 
health care, especially in countries without universal health coverage. In the 
Nordic countries, information on income is registered with the national tax office 
and routinely collected from all individuals. Furthermore, it is possible to obtain 
information about income before and after paying tax. In surveys it might be 
difficult to collect accurate information from patients regarding income as it 
might be considered a sensitive issue. Also, in several settings, even in Sweden, 
the individual might have another source of income from the black market and in 
this case it is not possible to ascertain the real income of the individual. 
Wealth is another indicator of SEP which reflects individual ownership 
regarding owning a house, savings, inheritance and others (65). 
Another common variable used in social medicine to indicate individual SEP is 
level of education. Nowadays, education is commonly used especially in the 
Nordic countries (17, 27, 66) and it can be accessed easily in national registers. 
Education can reflect the individual’s likelihood of employment and is strongly 
related to income and social status. Education level can also mirror an 
individual’s skill, general knowledge and health-related knowledge. The 
association between CHD and SEP is well known in both Sweden (67-74) and in 
other countries (75-80). Education has sometimes been considered to be more 
closely related than occupational status to heart disease (81, 82). The highest 
attained level of education has the advantage of being more constant as few 
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individuals continue schooling after age 35. Patients might be more willing to 
provide their education level rather than information about income and wealth. 
Furthermore, the association between education and disease may be less subject 
to reverse causality than income or occupation.  
2.3.1 SEP and CHD 
Inequalities in CHD incidence and mortality are complex, which may be 
due to multiple factors related to early childhood and adulthood life (83), 
behavioral and social risk factors (84) and access to care (85, 86). The 
association between low SEP and CHD may be explained by a higher prevalence 
of CHD risk factors (87-89) and CVD biomarkers (90, 91). However, a study 
have shown that the health disparities in different socioeconomic groups cannot 
be explained fully by the variations in risk factor levels (72). Furthermore, 
several studies have demonstrated that low SEP predicts CHD independent of 
traditional risk factors (79, 92-95). Fiscella and Tancredi explained the 
underlying pathways between SEP and CHD risk prediction (96). They believe 
that the association is likely to include biomedical (97), behavioral and 
psychosocial mediators (98). In addition, chronic psychosocial stress associated 
with low SEP induces atherosclerosis and CHD events (98). In addition 
individuals with a lower education level may confront more barriers to 
modifying their risk behaviors such as improving diet, quitting smoking, 
increasing physical activity and adhering to medications (27, 85) and 
cardiovascular interventions (86). 
2.4 HEALTH EQUITY 
Health equity and equality in access to healthcare are interrelated. The 
distinction between these two concepts has been discussed by others (99, 100). 
Health equity mainly refers to the justice, fairness and morality in providing 
healthcare especially for controllable aspects of health. Health inequity reflects 
dissimilarities in health that are avoidable, unjust, unfair and unnecessary (101). 
The disparities in health achievement reflect the health inequality. The reason 
for the disparity may be because of biological, genetic and age differences 
between individuals. For example, young individuals in general have better 
health than those who are older, and women may develop cervical or 
endometrial cancer whereas men may have testicular or prostate cancer. There is 
no suggestion that this is unfair. 
In some studies equality of access has been used as an practical definition of 
equity (102) with the term equity subdivided into horizontal equity – “a measure 
of equal treatment for those with equal need” – and vertical equity – “a measure 
of the extent to which individuals with unequal needs receive appropriately 
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different levels of care”. The equity in health can be measured using the 
distribution of resources, health status (incidence and outcome of the disease) or 
access to and utilization of healthcare between groups with different ethnic, 
demographic or socioeconomic background.  
The ethnic, socioeconomic and gender disparities in health and in access to 
healthcare are well documented (10, 13, 22-28, 103-107). In the USA, ethnic 
minorities receive lower quality of acute healthcare and less preventive care 
(107), and white children are more likely to receive routine healthcare than 
Hispanic children. The range of disparities varies among countries worldwide 
possibly due to differences in the availability of universal health coverage for all 
individuals in the country (105). In Sweden the coverage is universal. The 
Swedish Health and Medical Services Act of 1982 states that the health system 
must cover all legal residents. “Health and medical services are aimed at assuring 
the entire population of good health and of care on equal terms. Care shall be 
provided with due respect for the equal worth of all people and the dignity of the 
individual. Priority shall be given to those who are in the greatest need of health 
and medical care” (108).  
The Swedish Health and Medical Services Act give county councils and 
municipalities substantial freedom with regard to organization of their health 
services.     
 It is important to note that Sweden has universal health coverage with a 
universally financed health care system with small out-of-pocket payment. In 
addition Sweden has systematic approach to minimize the disparities in health 
outcomes and to improve quality of care. For example in order to improve care 
coordination, a new waiting time guarantee for the patient, was introduced in 
2005 and has been regulated by low since 2010 (108). This initiative, the 0–7–
90–90 rule, requires: ‘’instant contact (zero delay) with the health system for 
advice; seeing a general practitioner within seven days; seeing a specialist within 
90 days; and waiting no more than 90 days to receive treatment after being 
diagnosed’’. Despite all efforts there are still disparities in health in Sweden (11, 
46). Regardless of country of birth, there is inequality in obtaining adequate 
secondary prevention between educational groups (14, 17, 18, 66, 109, 110). 
2.5 CORONARY HEART DISEASE (CHD)  
CHD is a major component of the CVD. Health professionals frequently 
use the terms CHD and CVD interchangeably. CHD is also known as coronary 
artery disease (CAD), atherosclerotic heart disease, or ischemic heart disease 
(IHD). The five main manifestations of CHD are stable angina pectoris, unstable 
angina pectoris, myocardial infarction (MI), heart failure and sudden death. MI, 
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heart failure and sudden death., The incidence of MI in a population is often used 
as a proxy for measuring the CHD burden (111). CHD is a common term for the 
build-up of plaque along the internal walls of the coronary arteries, which leads 
to narrowing of the arteries and diminishes blood supply to the heart thus 
causing signs and symptoms of CVD including IHD and/or leading to MI. 
  
2.5.1 Statistics and epidemiology of CHD   
CHD remains the major cause of death worldwide (1-3) and in Sweden 
(5, 6). There has been a dramatic change in both the incidence of and mortality 
from MI in the past two decades. The number of MI-related deaths decreased 
from 18,000 in 1987 to 9000 in 2010. Between the years 2001 and 2003, the MI 
incidence was higher due to the introduction of new diagnostic criteria in 2001. 
Since 2004 there has been a decline in the incidence of and mortality due to MI. 
This decline has been dramatic; in 2011, the incidence was approximately 30% 
lower among both men and women compared to the year 2001 (5, 6). 
There are several approaches to conducting epidemiological studies of global 
heart disease. Véronique L. Roger (111) has mentioned some examples of these 
established studies and surveillance such as the National Hospital Discharge 
Survey, community surveillance, Atherosclerosis Risk in Communities (ARIC), 
The Minnesota Heart Survey, Olmsted County Study, Framingham Heart Study, 
the Corpus Christi Heart Project, the WHO MONICA project and the Global 
Registry of Acute Coronary Events. Each of these studies used different 
methodology within well-defined populations and provided complementary 
information. Some were designed to analyze diverse ethnic groups such as ARIC 
and the Corpus Christi Heart Project whereas others had more limited ethnic 
diversity. Roger suggested the need for a national surveillance approach for 
epidemiological studies of CHD. This would provide better understanding of 
heart disease in the population. High-quality and complete nationwide 
surveillance can be achieved in Sweden because of the national health data 
registers. 
Regional studies using appropriate designs to provide data on epidemiology of 
MI have been conducted in Sweden. The Stockholm Heart Epidemiology 
Program (SHEEP) is one of the largest population based case–control studies 
(14). SHEEP contains data about patient’s characteristics and lifestyle factors as 
well as biomarkers. In addition, the unique Swedish registers provide excellent 
opportunities for population statistics and for conducting nationwide 
epidemiological studies on MI. A national record linkage between the National 
Patient Register and the Causes of Death Register was initiated in 1996 to 
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provide statistical information about acute MI (AMI) in Sweden (112). It is 
currently covering the period 1987–2011. This database provides data for 
monitoring MI, including information on incidence rates and case fatality, and 
can measure the true population burden of MI and how it may have changed 
over time. The possibility to link several sources of background information in 
Sweden makes it possible to conduct high-quality analytical research on the 
etiology of MI. 
In summary, epidemiological studies provide data about the incidence and 
outcome of MI which is essential for determining the burden of MI in the 
population. Also, the analytical studies provide clues to the understanding of the 
etiology of MI.    
2.5.2 Myocardial infarction (MI) 
AMI is a condition caused by sudden deterioration of blood flow in the 
coronary blood vessel and thereby ischaemia within the heart muscle. The 
underlying cause is usually a rupture of an atherosclerotic plaque (plaque 
rupture). Atherosclerosis in the wall of coronary arteries is the gradual build-up 
of cholesterol and fibrous tissue in atherosclerotic plaques (113). Plaque rupture 
occurring in the coronary vasculature leads to AMI (114, 115). The phrase ‘acute 
coronary syndromes’ is also used in a clinical setting; this term includes unstable 
angina, non-ST-elevation MI (NSTEMI) and ST-elevation MI (STEMI), 
according to the appearance of the electrocardiogram (ECG), and sudden cardiac 
death (116, 117). 
2.5.2.1 Definition of MI 
The WHO has had a leading role in the formulation of standard criteria 
for the definition and diagnosis of MI and CHD (116, 118-120). In the early 
1970s, the definition of MI was based on WHO European acute MI registry 
criteria and then further revised in 1979 by the International Society and 
Federation of Cardiology (116, 120). In 1979 the definition was primarily based 
on ECG changes (120, 121) and then shifted towards a biochemical and clinical 
approach in 2000 (121-123). In 1979, the diagnostic criteria were reported (120). 
In 2000, collaboration between the European Society of Cardiology (ESC) and 
American College of Cardiology (ACC) lead to a new definition of MI. The 
redefinition of MI was important in the cardiology field, coinciding with the 
introduction of a new cardiac biomarker, troponin, for the diagnosis of MI (122). 
The ESC and ACC consensus document for the redefinition of MI was published 
in September 2000, including a summary of the diagnostic criteria (122).    
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The second joint document for defining MI was published in 2007 when the ESC 
and ACC were joined by the American Heart Association (AHA) and the World 
Heart Federation (WHF). In this consensus document, the use of troponin as a 
primary biomarker was recommended (121, 124, 125). There was debate about 
the 2007 universal definition of MI. WHO claimed that the definition was only 
suitable for countries with high-quality resources and not for resource-poor 
countries, i.e. that it was only appropriate for Europe and North America (121).  
The third universal definition of MI in 2012 was a consensus document between 
the ESC, American College of Cardiology Foundation (ACCF), AHA and WHF 
and included members from 52 countries including China and Russia. The 
sections of the document concerning detection of MI using ECG and imaging 
techniques were revised in 2007 document. The consensus document included 
both updated definitions and a revised classification of MI which have 
significant clinical, epidemiological and research implications (126). 
2.5.2.2 Clinical classification of MI 
In 2007, for the first time in the history of MI definition, the global task 
force classified MI into five different types. “The 2007 document was more 
widely accepted by clinicians” (121). In Sweden the 2007 criteria for 
classification of MI (125) were used until 2012. The 2007 criteria were as 
follow:  
“Type 1 Spontaneous myocardial infarction related to ischaemia due to a 
primary coronary event such as plaque erosion and/or rupture, fissuring, or 
dissection.  
Type 2 Myocardial infarction secondary to ischaemia due to either increased 
oxygen demand or decreased supply, e.g. coronary artery spasm, coronary 
embolism, anaemia, arrhythmias, hypertension, or hypotension. 
Type 3 Sudden unexpected cardiac death, including cardiac arrest, often with 
symptoms suggestive of myocardial ischaemia, accompanied by presumably 
new ST elevation, or new LBBB, or evidence of fresh thrombus in a coronary 
artery by angiography and/or at autopsy, but death occurring before blood 
samples could be obtained, or at a time before the appearance of cardiac 
biomarkers in the blood.  
Type 4a Myocardial infarction associated with PCI.  
Type 4b Myocardial infarction associated with stent thrombosis as documented 
by angiography or at autopsy.  
Type 5 Myocardial infarction associated with CABG”. 
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The modified classification of MI was published in October 2012 by the Global 
myocardial Infarction Task Force.2, (126). 
 
2.5.2.3 Recurrent MI 
The difference between recurrent MI and reinfarction is sometimes 
unclear. Recurrent MI refers to when a new MI occurs after day 28 following a 
first MI. However, if characteristic features of MI occur within the first 28 days 
after an incident MI, this is not considered as a new MI event for the public 
health and epidemiological purposes. This instead referred to as a reinfarction, 
i.e. when a “new” MI occurs within 28 days of a first incident MI or recurrent 
MI (116, 126). The criteria for definition of reinfarcton have been reported (126). 
2.5.3 Management of MI 
Management of this disease includes diagnosis (history, clinical 
examination and investigation), treatment (acute and long-term medical therapy) 
and secondary prevention. MI is an acute emergency condition; it is critical to 
rapidly diagnose MI to be able to provide correct treatment in order to save the 
life of the patient. Therapy varies according to the type of MI (STEMI or 
NSTEMI), but the first main goal is the same: to restore perfusion and prevent 
and minimize ischaemia by medical therapy/and or interventional and surgical 
measures such as percutaneous coronary intervention (PCI) or CABG. The next 
step is long-term therapy and the secondary prevention of MI in order to limit 
complications and further recurrence to decrease morbidity and mortality (127, 
128).  
2.5.3.1 Treatment and long term Pharmacotherapy  
Drug therapy is a core component of the management of CHD in both 
the acute phase and in long-term treatment. The choice of a medical treatment 
depends on the specific situation and varies from one individual to another. 
Pharmacotherapy and secondary prevention are necessary and should be 
accessible for all patients (129). The 2002 ACCF/AHA guidelines are useful for 
the long-term medical therapy and secondary prevention of CHD (130). The 
guidelines recommend use of the ‘ABCDE concept’: aspirin, anti-anginals and 
angiotensin-converting enzyme (ACE) inhibitors (A); beta-blockers and blood 
pressure (B); cholesterol and cigarettes (C); diet and diabetes (D); and education 
and exercise (E).   
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There are drugs essential for primary and secondary care for MI (128). All 
patients who have had a history of MI and those who have undergone 
myocardial revascularization should be offered treatment with a combination of 
medication. Several drugs (antiplatelet agents, beta-blockers, ACE-inhibitors, 
and statins) are well-known to improve prognosis of MI patients (131-138). 
 
 Aspirin: reduces cardiovascular mortality and morbidity. Aspirin has a 
protective effect in most patients with increased risk of vascular 
occlusive events, including those with an AMI, previous MI, stable or 
unstable angina and ischaemic stroke (132, 133, 139) 
 Beta-blockers: administered long terms to patients after MI have been 
shown to improve survival and reduce total mortality and cardiovascular 
morbidity (132, 138, 139). 
 ACE inhibitors: are effective in reducing mortality, the risk of MI and in 
certain patients the risk of developing heart failure (132, 135, 136, 140-
142). 
 Statins: are essential for the prevention of cardiovascular events. These 
agents reduce total mortality and cardiovascular morbidity (132, 134, 
139, 143). 
2.5.4 Coronary artery bypass grafting (CABG) 
In late 1960s, CABG was introduced to treat the symptoms of obstructive 
CHD (144). The operation is documented as an effective treatment in a high 
proportion of patients with CHD (145-147). During the last decade a decline in 
the number of CABG procedures has been observed due to the advent and 
expansion of percutaneous coronary interventions (PCI) (148-150). In Sweden, 
the number of heart operations has continues to decrease slightly in comparison 
with the preceding year. In 2013, a total of 5, 760 open heart procedures were 
reported in Sweden. Fewer isolated CABG procedures were performed,  2, 575 
operations compared with 2, 705 during 2012 (5). 
2.5.5 Risk factors of CHD 
There are several risk factors for heart disease; the most well-known non-
modifiable and modifiable risk factors are age, sex, family history and genetics, 
as well as dyslipidemia, smoking, hypertension, glucose intolerance, central 
obesity, and psychosocial factors (151-153).  
Non-modifiable risk factors: The risk of emerging CHD increases with age 
(154), and men develop heart attacks at ages >45 years i.e. younger than women 
who develop the disease >55 years, also mortality rates tend to be higher for men 
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(155). It has been found that, on average, women experience a first MI 9 years 
later than men (156). A family history of early-onset CHD in first a degree 
relative (father or brother with CHD at age 55, and mother and sister at age 65), 
has been considered a risk factor for CHD (157). Ethnicity as a non- modifiable 
factor has also been investigated; previous studies showed ethnic differences in 
the development of CHD and atherosclerosis (158, 159).  
Modifiable risk factors: The results of many studies have suggested that 
smoking, dyslipidaemia and blood pressure are the most significant factors with 
regard to IHD incidence and mortality (160-162). Furthermore controlling for 
these risk factors by continued management of blood pressure, dyslipidemia, 
diabetes, and life style changes (exercise, healthy diet and cessation of smoking) 
(153, 163) has a considerable impact on disease prevention and reduction of 
premature death (89, 164).  
Studies have shown a strong relationship between cigarette smoking and heart 
disease. In 2000, it was estimated that 800,000 deaths due to CHD could be 
attributed to smoking (165). Cessation of smoking leads to a reduced recurrence 
rate within 1 year among patients who have had an MI and decreases the risk of 
sudden cardiac death among patients with CHD (166).
 
Termination of smoking 
leads to reduction of recurrence rate within 1 year among patients who have had 
MI and decreases the risk of sudden cardiac death among patients with CHD 
(166, 167).  
An abnormal lipid profile is the main contributor to CVD globally. The findings 
of the INTERHEART study demonstrated that tobacco was the second main risk 
factor after lipid profile. Other common risk factors are hypertension, diabetes, 
abdominal obesity and psychosocial factors (89). Some of these risk factors are 
correlated to each other. Subsequent studies confirmed that dyslipidemia is a 
significant risk factor (160-162) and further established that raised triglyceride 
levels increase CVD risk. Furthermore, reduction of low-density lipoprotein 
(LDL) cholesterol is important in both primary and secondary prevention of 
CHD. These findings have been confirmed in many studies (168, 169). Recent 
clinical trials showed that lowering LDL cholesterol by intensive lipid-lowering 
therapy reduces the rate of MI and mortality (170). The reduction in cholesterol 
was the most important factor in the overall decline in CHD mortality in Finland 
between the 1970s and early 1990s (171). 
Abnormal blood pressure has an impact on the risk of CVD, increasing the risk 
2-fold compared with healthy individuals (172). Diabetic patients are more prone 
(2- to 8-fold increased likelihood) to develop CVD in the future (173, 174). 
Furthermore CVD is an important cause of morbidity and mortality in diabetic 
patients (175, 176). Obesity is the main risk factor for type 2 diabetes, but 
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unhealthy diet and physical inactivity have been shown to be independent risk 
factors for diabetes (177). 
Furthermore other life style and psychosocial factors are associated with risk of 
MI and have an important role in increasing CVD risk at all ages and in both 
sexes (89). Depression, life stressors, anxiety, anger and lack of social support 
are factors that have been associated with CVD (178-180). Such factors have 
been linked to the increased risk of sudden death, and recurrent MI. Anxiety and 
chronic stress have also been linked to negative behaviours such as low physical 
activity and poor diet and have an impact on CVD outcomes (178, 179).
 
Other diseases are linked to CVD including chronic inflammatory disorders such 
as systemic lupus erythematosus and rheumatoid arthritis (181, 182). 
Furthermore CHD is due to a complex interaction between environmental factors 
and numerous genetic variants. The first known genetic variant for CHD was 
discovered by a genome-wide association study of chromosome 9p21.3. The 
increased risk for MI detected with single-nucleotide polymorphisms from the 
9p21.3 (183-185). 
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3 AIMS 
3.1 OVERARCHING AIM 
The overarching aim of this thesis was to increase knowledge of the effect 
of country of birth on management, prognosis, and access to health care services 
in patients with CHD in Sweden.  
 
3.2 SPECIFIC OBJECTIVES 
 To study the incidence and time trends of MI in relation to country of 
birth, SEP, gender and age (Study I).  
 To investigate mortality after 28 days following an incident MI in 
relation to country of birth, SEP, gender and age (Study I). 
 To investigate cardiovascular drug use after first MI in relation to country 
of birth, SEP, gender, age and drugs used before MI (Study II).  
 To evaluate the risk and trend of recurrent MI in Sweden in relation to 
country of birth, SEP, gender and age (Study III).  
 To determine the effect of duration of residence and age at immigration 
on recurrence of MI (Study III). 
 To study mortality after CABG in relation to country of birth, SEP, 
gender and age (Study IV). 
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4 MATERIALS AND METHODS 
4.1 SWEDISH PERSONAL IDENTITY NUMBER 
The Swedish personal identity number (PIN) is vital in many aspects of 
Swedish society and serves as a unique identifier in Swedish healthcare and 
national registers. The PIN was established in 1947. From 1967 the 10-digit PIN 
has consisted of the date of birth, a three-digit birth number and a single check 
digit. The three-digit number can take any value between 001 and 999, and is 
odd for men and even for women (i.e. is sex specific) (186). The PIN was 
principally a useful means of identifying individuals. Nowadays it is widely used 
in public administration, vital statistics, for research purposes, and as the key 
variable for linkage and matching between different national demographic 
registers and health data registers, quality registers in healthcare  and biobank 
(187). A person who is born in Sweden or who moves to the country and intends 
to stay for at least 1 year will receive a PIN, and is thus entered in the Total 
Population Register. The PIN is unique to each individual, and preserved for life. 
Individuals remain registered in Sweden until the day they move abroad or die 
(188). 
4.2 LINKAGE TO SWEDISH NATIONAL REGISTERS 
Two main authorities handle register linkage for health research purposes: 
Statistics Sweden and the National Board of Health and Welfare (186). The data 
used in our study were collected by linkage to several national registers through 
the PIN. The data used are based on the newly established Migration and Health 
Cohort (189) specifically designed to address health status among immigrants in 
Sweden. This database serves as a link between more than 15 national registers 
including cancer, CVD, diabetes, injury and psychiatric disorders among 
foreign-born persons and their descendants. 
4.3 TOTAL POPULATION REGISTER (TPR) 
Sweden is one of the countries with oldest population statistics, with 
continuous information dating back to the 18th century. In 1968, the national 
civil registration was computerized and the Total Population Register (TPR) was 
established. From 1969, the TPR has been the base register for authorized 
Population Statistics in Sweden (190). The TPR comprises most of the data 
found in the civil registration, and covers the entire population resident in 
Sweden. 
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 The Swedish Tax Agency is in charge of the population register (188). 
The following information included in the register (188): 
 Name 
 Address 
 Personal identity number and co-ordination number 
 Place of birth (country, county, and parish) 
 Place of residence (region and address) 
 Citizenship 
 Civil status (never married, married, partner, divorced, widow/widower) 
 Spouse, children, parents, legal guardians and adoption 
 Moves to and from Sweden 
 Addresses abroad 
 Death and burial site. 
 Sex 
 Age 
 Immigration (date, country, ground for settlement) 
 Relations (married couples, child – parent) 
Dates are also added to the register, e.g. wedding date (188). The quality of the 
TPR is generally very high. However, it is suspected that there may be an under-
reporting of information, foremost of emigration from the country (i.e. persons 
moving out of Sweden without notifying the authorities), although the exact 
magnitude of this is unknown (191, 192) . To be registered as an immigrant in 
Sweden one must intend to stay in Sweden for at least 1 year. Likewise, 
registration as an emigrant requires that the person emigrating must intend to 
reside abroad for at least 1 year.  
4.4 CAUSES OF DEATH REGISTER  
The Causes of Death Register is managed by the National Board of Health 
and Welfare and comprises data from 1961 updated annually. There is also a 
historical mortality register for the years 1952-1960 (193). International 
Classification of Diseases (ICD) (ICD-6) was adopted by the World Health 
Assembly in 1948 and introduced in Sweden in 1951. Newer revisions of the 
ICD were introduced in 1958 (seventh revision), 1969 (eighth revision), 1987 
(ninth revision) and 1997 (tenth revision) (194, 195). The Causes of Death 
Register covers all deaths among individuals who were registered in Sweden in 
the year they died, whether the death occurred inside or outside the country. The 
register does not include stillbirths, or persons who died during a temporary stay 
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in Sweden or asylum seekers who have not yet received a residence permit. 
Swedish emigrants, who are no longer registered in Sweden, are also excluded 
(193). When the death of a Swedish citizen occurs inside Sweden, a physician 
will submit a death certificate to the Swedish Tax Agency. If the death occurs 
abroad, the Swedish embassy or consulate in that country shall inform the 
Swedish Tax Agency as soon as they are aware of the death (188). The register 
contains: 
 Personal identity number 
 Place of death  
 Underlying and contributing cause of death  
 Date of death  
 Sex, marital status and age 
The quality of death registers can be influenced by the age of the deceased 
individual. An elderly person may have a more complicated cause of death 
compared to a young person, and it might be difficult for the physician to write a 
precise death certificate in some circumstances (191). Autopsies also provide 
good information regarding cause of death however, the number of autopsies 
have gradually decreased from 50 % during the 1970 to 14% in recent years 
(191, 196). The National Board of Health and Welfare aims to count all deaths 
among Swedish residents, whether or not the death was in a Swedish citizen and 
whether the death occurred inside Sweden or abroad. However, in 1.9% of all 
deaths reported to the TPR, the national Board of Health and Welfare was not 
able to obtain a death certificate. The register has a wide range of applications 
for Swedish statistics and for medical research. 
4.5 NATIONAL PATIENT REGISTER 
At the beginning of 1960 the National Patient Register (NPR) covered 
six out of the 26 county councils in Sweden. The NPR was started in 1964 and 
became nationwide in 1987 (including all inpatient care in Sweden). From 
2001, it has recorded somatic and psychiatric specialized outpatient visits from 
both private and public caregivers including day surgery. From the period 
1964–2006, 50 million discharges were recorded (197). The register includes 
patients’ data, geographical data, admission and discharge dates, and data on 
the hospital or clinic in which a patient was treated, as well as some data on 
type of admission, diagnoses and procedures. The quality of the NPR is very 
high. Regular quality control of the PIN, hospital, main diagnoses and 
secondary diagnoses, and admission and discharge dates is conducted. 
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The validity of the Swedish NPR is high for many variables. Of all admissions 
during the period 1987–2011, only 1.1% of primary diagnoses were missing 
from this register. For somatic care, the proportion of missing data is below 1%.  
Data from this register are useful for large-scale population-based research. For 
some diagnoses and for certain research areas the use of other health registers is 
recommended. For instance, the Swedish Cancer Register is more appropriate 
for studies on cancer incidence (198). Of note, there is no national register for 
primary healthcare in Sweden. 
4.6  ACUTE MYOCARDIAL INFARCTION DATABASE  
The nationwide Acute Myocardial Infarctions (AMI) database was 
introduced in 1996 by a record linkage between the NPR and the Causes of 
Death Register. It comprises all AMIs reported to either register and is updated 
annually by the National Board of Health and Welfare. It covers the whole 
country from 1987. In most cases the MI patient can be identified in a population 
because MI is an emergency condition and patients either die or are treated in 
hospital. The main variables in the AMI database include PIN, sex, age at 
diagnosis of MI, birth date and dates of admission, discharge and incidence of 
MI. The quality of the database has been evaluated and found to be very high 
(199). There is no information on those who have been admitted to hospital from 
abroad due to an MI, as the NPR is an administrative register only covering care 
in Sweden (200). 
4.7 THE SWEDISH HEART SURGERY REGISTER 
In addition to the national health data registers Sweden also has several 
national quality registers. These registers are not covered by the same regulations 
as the national health data register. Hence, reporting from the health care 
providers to these registers is voluntarily, and the patients can also deny to be 
reported in these registers. This is in sharp contrast to the national health register 
where the health care providers must report all in-patient care and all specialized 
out-patient care, and the patients cannot deny recording. 
Since the establishment of Swedish Heart Surgery in 1992, all open-heart 
surgery performed in Sweden is reported to this national quality register that has 
complete coverage. It contains data about more than 100 000 heart operation. All 
heart operations including coronary artery bypass graft (CABG) are included 
yearly with demographic data, information on type of operation, certain 
postoperative complications and risk factors according to Euro SCORE 
(European System for Cardiac Operative Risk Evaluation). Diseases are coded 
according to present ICD-codes and surgical procedures according to the 
Swedish version of Nordic Medico-Statistical Committee (NOMESCO) (201). 
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Open heart surgery procedures including CABG were more than 7 000 during 
1992.  The maximum was in 1994 with 9 512 operations. From 2002 to 2008, 
cardiac surgery decreased by 20%. The number of isolated CABG procedure 
decreased by 44% during the same period.  
The register is a reliable source of data for heart surgery. Information is reported 
to the register on-line or on a designated report card including up to 101 items (5, 
202). In January 2010, the web-system was established in Sweden for patient 
with admitted to hospital because of acute coronary syndrome. 
4.8 PRESCRIBED DRUG REGISTER 
In Sweden, a national register of dispensed drugs was established in July 
2005. It covers the whole Swedish population with valuable data for all 
dispensed drugs. The Swedish Prescribed Drug Register represents one of the 
largest population based pharmacoepidemiological records in the world and can 
offer new possibilities for local and international pharmacoepidemiological 
research. The potential for research by record linkage to other health registers is 
huge. Data gathering is managed by the National Corporation of Swedish 
Pharmacies and the register is regulated under Swedish legislation (27, 203). All 
drugs are classified according to the Anatomical Therapeutic Chemical (ATC) 
classification system (204).  
The register contains the following data: dispensed item – substance, brand 
name, formulation and package; dispensed amount – dosage and expenditure; 
age, sex and unique identifier (PIN); place of residence – county, municipality 
and parish;  date of prescribing and dispensing; practice (primary healthcare 
center or hospital clinic) that has issued the prescription, identified by a code; 
and the prescriber’s profession – e.g. general practitioner, internal medicine 
specialist, psychiatrist or paediatrician (203).  
The indication for medication is not available and the register only covers 
dispensed drugs i.e. information about prescribed drugs by the physician which 
are not collected by the patient are not recorded. The register does not contain 
records on treatments used in hospitals, in nursing homes and is not complete 
with regard to information about vaccination. Over-the-counter drugs (OTC) are 
not recorded. 
4.9 THE SWEDISH NATIONAL POPULATION AND HOUSING 
CENSUS  
The Swedish National Population and Housing Census contain 
information on the total population of Sweden between 1960 and 1990. The 
information is updated every 5 years from a questionnaire delivered by post to 
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every household in Sweden. The census includes demographic and 
socioeconomic data as well as information on housing and employment for 
each household member resident in Sweden.  
4.10 LISA  
Longitudinal Integration database for health insurance and labor market 
studies (LISA) is a database linked to information from several registers. LISA 
was established in 1990 and the information is updated annually. It contains 
data incorporated from the labour market and from educational and social 
sectors, and includes demographic, occupational and socioeconomic variables 
such as individual, family and capital income, education and marital status.  
The benefit of LISA is that it permits follow-up over time of an individual’s 
status. LISA is a compilation of many other registers with more detailed 
information. In addition, it comprises thorough information on sickness leave, 
parental leave, unemployment and social insurance (205). 
 
4.11 ETHICS STATEMENT  
All the studies included in this thesis were approved by the Regional 
Board of the Ethical Committee at Stockholm. (Dnr: 2005/726-31, 2008/945-32 
and 2009/587-32). Ethical vetting is always required when using register data for 
research in Sweden. The ethical review board provides the researcher with the 
anonymized data. The real personal identity number (PIN) is replaced by a serial 
number by the National Board of Health and Welfare or statistics Sweden to 
ensure the confidentiality. In the present project the linkage has been completed 
via 10-digit PIN. The personal integrity was not violated. By Swedish law data 
recording to national health data registers, like the NPR, do not require consent 
from the patients, nor from the health care providers. It is obligatory to report to 
these registers, and the patients cannot decline registration. One argument is that 
the possibility to work with this anonymized data for research purposes is of 
benefit to society and the benefit overrides the potential harm. The quality health 
care registers, like the Heart Surgery Register, are voluntary and the patients 
must be informed about the register, but they do not need to give written or oral 
consent to be recorded. However, patients can at any time decide to not allow 
registration in these quality health care registers. The researcher has to protect 
the personal integrity and follow the ethical rules regarding security of the data 
storage and agree to never back track to the identity of the individual (186). We 
present data for immigrants from specific countries; this may be regarded as a 
kind of stigmatization for people from these countries. However, we feel it is of 
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great importance to highlight these country specific data in order to improve 
public policy, health and health care for these populations. 
 
4.12 METHODS 
The data sources for all four studies are derived from Migration and Health 
Cohort (189) (Table 2). The two main groups in all studies were Sweden born 
individuals (those born in Sweden) as a reference group and foreign-born 
individuals (those born outside Sweden) as the exposed group. The analyses 
were stratified by sex. 
4.12.1 Study period 
Study I 
Incidence of MI: Individuals were followed from 1 January 1987, first 
immigration date for foreign-born or the first date at age 35 years old, whichever 
occurred last, until the date of diagnosis of an acute MI, first emigration date, 
death, first date at age 90 years old, or end of follow-up (31December 2008), 
whichever occurred first. 
Mortality after MI (Case fatality): Non-fatal MI cases were followed from the 
date of diagnosis until the date of death due to MI either as an underlying or 
contributory cause, death due to other causes, first emigration date, first date at 
age 90 years, or end of follow-up (31 December 2008), whichever occurred first. 
Case fatality was mentioned because we followed MI cases. 
Study II The study population consisted of all incident cases with a first AMI 
during the study period (1 January 2006 to 31 December 2007). The study was 
restricted to those patients who survived at least 6 months after AMI.  
Study III Patients were followed from the date of first MI until the date of 
second MI, date of first emigration, date of death, or end of follow up (31 
December 2007), whichever came first. 
Study IV Patients were followed from the date of CABG until the date of death 
from any cause, date of emigration or end of follow-up (31 December 2007), 
whichever came first. 
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4.12.2 Exposure variables 
The main exposure variable in this thesis was Migration status (country of birth) 
(Table 2) and to more extent country of birth. For all four Studies, we classified 
foreign-born We classified foreign-born individuals according to six continents, 
which were subdivided into 19 world regions, as defined by the United Nations 
Population Division (206) (Studies I, II, III and IV): 
Africa (Eastern, Central, Northern, Southern, and Western Africa), 
Asia (Eastern, South-Central, South-Eastern, and Western Asia),  
Europe (Eastern, Northern, Southern, and Western Europe),  
Latin America (Caribbean, Central America, and South America),  
North America (USA and Canada) and Oceania (Australia/, New Zealand, 
Melanesia, and Micronesia, Polynesia), 
For Study II, we included the following categorization:  
Sweden (individuals born in Sweden);  
Nordic (individuals born in Finland, Denmark, Norway or Iceland); 
EU-countries and Switzerland (individuals born in EU); 
Other-European countries (individuals born in Europe but outside the EU); 
Outside-EU (individuals born outside Europe) 
In addition, we dichotomized patients as born in Sweden or not. We reported 
information for all continents and regions, as well as for all individual countries 
with five or more outcome.  
We also studied the association between SEP (in all four studies) and sex in 
(Studies I, III, IV) and outcome when it was applicable in our studies. We used 
the highest attained level of education as an indicator for SEP. We divided levels 
of education into four categories: 0–9 years (compulsory school education), 10–
12 years (upper secondary), more than 12 years (post-secondary), and unknown. 
Also, age at immigration (younger than 14, 15–39, 40–64, and 65 years +) and 
duration of residence in Sweden (less than 14 years, 15–34, and 35 years +) were 
investigated in Study III. 
4.12.3 Outcome variables 
Different end points related to CHD were the outcomes of interest: First, 
MI (study I), death due to MI as an underlying cause or contributing cause of 
death, and death due to any cause (Study I), odds of cardiovascular drug use 
(Study II), fatal and non-fatal second MI (Study III) and death due to any cause 
(Study IV). Drugs prescribed after MI included in Study II were: acetyl salicylic 
acid (ASA) and clopidogrel (ATC codes: B01-AC04, B01AC06; defined as C), 
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beta-blockers (C07; defined as B), lipid-lowering drugs (C10; defined as L), 
ACE inhibitors (C09; defined as A) and vasodilators nitrates (C01; defined as 
N).  Drugs were grouped into five categories: i) recommended drugs or adequate 
combinations of recommended drugs (LBAC, BAC or BC); ii) Other, other 
combinations of recommended than (LBAC), (BAC) or (BC)); and iii) None of 
the recommended drugs. According to Swedish guidelines on drug use in CVD, 
drugs are ranked on a scale from 1 to 10. The medication considered to be of 
highest priority is assigned rank order 1. The first three combinations (LBAC, 
BAC and BC), in our categorization of drug use after MI are ranked first, second 
and third, respectively, according to the guidelines. Only prescriptions filled 
within 180 days after MI were studied.  
4.12.4 Explanatory variables 
Study I:  age, education, comorbidities, and calendar years of follow-up. Age 
was divided into eleven groups in 5-year intervals (35–39, 40–44… 85–89 
years). We divided study period into four time periods (1987–1990, 1991–1995, 
1996–2000 and 2001–2008). Comorbidities (diabetes, hypertension and 
hyperlipidaemia) were considered in the analysis as binary variable (yes/no). In 
all four studies highest attained level of education was used as a proxy for SEP 
and we divided levels of education into four categories as described above.  
 Study II: age, sex, education, diabetes and marital status. Age at diagnosis of 
MI was divided into four groups (younger than 60, 60–69, 70–79 and 80 years 
and older). Diabetes was considered in the analysis as a binary variable (yes/no). 
With regard to marital status, we have classified married and register partners as 
married and all others as unmarried.   
Study III: age, calendar year of follow up of first MI, and educational level. Age 
was divided into eight groups (30–49, 50–54, 55–59, 60–64 . . . , and 80–84 
years). We divided study period into four intervals: 1987–1990, 1991–1995, 
1996–2000, and 2001–2007.  
Study IV:  age, calendar year of surgery, waiting time for surgery, diabetes 
mellitus and education. Age at surgery was divided into five groups (younger 
than 50, 50–59, 60–69, 70–79 and 80 years and older). The year of surgery was 
divided into three groups (1995–1998, 1999–2002 and 2003–2007). Waiting 
time for surgery was categorized into five groups (as an emergency within 24 
hours, 1–6 days, 7–30 days, 31–90 days and longer than 90 days). Diabetes was 
considered in the analysis as a binary variable (yes/no). 
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 Table 2. An overview of the four studies 
 Study I Study II Study III Study IV 
Aim 
To study the incidence and the time trends of MI and to 
investigate mortality after 28 days following an incident 
MI in relation to country of birth, SEP, gender and age 
To investigate cardiovascular drug use 
after first MI in relation to country of 
birth,  SEP, gender, age, and drugs 
used before MI 
To evaluate the risk and trend of 
recurrent MI in Sweden in relation to 
country of birth, SEP, gender, and age. 
To determine the effect of duration of 
residence and age at immigration on 
recurrence of MI 
 
To study mortality after CABG in relation 
to country of birth, SEP, gender and age 
Study 
population 
Swedish Total population  (n=3, 426,243 men and 3, 
326,412 women) and all non-fatal first MI patients 
(n=224, 498 men and 141, 587 women, of which 35, 066 
were foreign-born (21, 431 men and 13, 635 women)) 
(1987-2008) 
All non-fatal first MI patients 
including n= 37, 570 (of whom 4, 782 
(12.7 %) were foreign-born, who 
survived at least 180 days after MI ) 
(2006-2008) 
All non-fatal first MI patients 
including n=469, 261 (Sweden-born: 
300, 715 men and 168, 546 women) 
and 49, 242 foreign-born: 31, 033 men 
and 18, 209 women). (1987-2007)  
All individuals who underwent a first 
isolated CABG including n= 72, 333 
(Sweden-born: 48, 301 men and 14, 855 
women) and foreign-born: 6, 685 men and 
2, 492 women). (1995-2007) 
Design  Cohort study Cohort study Cohort study Cohort study 
Data 
sources 
Migration and health cohort including: National patient 
Register, Causes of death register, Total Population 
register, Swedish Population and Housing Census and 
longitudinal integration database for health insurance 
and labour market  
Migration and health cohort including: 
National patient Register and Causes 
of death register (Myocardial 
infarction Database), Prescribed Drug 
register, Total Population register, 
Swedish Population and Housing 
Census and longitudinal integration 
database for health insurance and 
labour market   
Migration and health cohort including: 
National patient Register and  Causes 
of death register (Myocardial 
infarction Database), Total Population 
register, Swedish Population and 
Housing Census and longitudinal 
integration database for health 
insurance and labour market 
Migration and health cohort including: 
The Swedish Heart Surgery Registry, 
Swedish Coronary Angiography and 
Angioplasty Registry (SCAAR) and the 
Register of Information and Knowledge 
about Swedish Heart Intensive Care 
Admissions (RIKS-HIA), The Register of 
the Total Population, Causes of  Death 
Register, and the Swedish Population and 
Housing Census and the longitudinal 
integration database for health insurance 
and labor market studies 
Main 
exposures 
Country of birth and SEP Country of birth and SEP Country of birth and SEP Country of birth and SEP 
Main 
outcomes 
First MI incidence and mortality after MI Filled prescriptions after MI Recurrent MI Mortality after CABG 
Statistical 
analysis 
Poisson regression and Cox proportional hazard 
regression 
Logistic regression Cox proportional hazard regression Cox proportional hazard regression 
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5 STATISTICAL ANALYSIS 
5.1 COX PROPORTIONAL HAZARD REGRESSION 
We used multivariate Cox proportional hazard regression in Studies I, III 
and IV to model risk of first MI case fatality, second MI and mortality after 
CABG, respectively. The most commonly applied model in medical time-to-
event studies is the Cox proportional hazards model, i.e. a multiplicative 
association between the underlying hazard functions and a log–linear function of 
the covariates. The model assumes proportionality of hazards; it is assumed that 
the hazards for patient subgroups are proportional over the follow-up period (the 
two hazard curves are thus assumed to be parallel on a log scale). Hazard ratios 
(HRs) with 95% confidence interval (CIs) were used to compare different 
groups. The assumptions of Cox regression were examined using a martingale-
based graphical and numerical approach.  
5.2 LOGISTIC REGRESSION   
Logistic regression is a form of regression modelling that is useful to predict a 
binary response variable. The probability of success is modelled as a function of 
a set of covariates, x1… xq. The odds ratio (OR) with 95% CI was calculated to 
compare the odds of drug use after MI among different groups.  
5.3 POISSON REGRESSION  
We used Poisson regression to calculate incidence rate ratios (IRRs) of first MI 
with 95% CI (Study I) in an adjusted analysis. Poisson regression is a 
generalized linear model in which the response variable is assumed to follow the 
Poisson distribution. 
5.4 JOINTPOINT REGRESSION  
To analyse the time trends of first MI we used the Jointpoint regression model 
(Study I). The processes in the analysis using Jointpoint regression involve 
fitting a series of joined straight lines on a log scale to the trend of incidence 
rate data for age-standardized rates.  The change in trend in each point can be 
identified when it is statistically significant. The program starts with the lowest 
number of jointpoints and checks whether more jointpoints are statistically 
significant and must be added to the model. The annual percentage change 
(APC) can be estimated by this method to denote the trend and to test statistical 
significance. The null hypothesis in the analysis using this method is that there 
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is no alteration in the trend of incidence rates, i.e. neither increasing nor 
decreasing (191). 
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6 RESULTS 
6.1 STUDY I   
Incidence and case fatality after day 28 of first time myocardial infarction in 
Sweden 1987-2008   
Aim: 
To study the incidence and time trends of MI in relation to country of birth, SEP, 
gender and age  
To investigate mortality after 28 days following an incident MI in relation to 
country of birth, SEP, gender and age 
Incidence of MI 
During the study period (1987–2008) we observed 571,476 cases of first-time 
MI (344,349 men and 227,127 women), of which 49,735 were in foreign-born 
individuals (29,655 men and 20,080 women). In both sexes and regardless of 
country of birth, a decreasing trend in first-time MI incidence was observed. The 
trend was, however, less pronounced among women and those born outside 
Sweden. Men had a higher incidence of MI than women (IRR 2.09, 95% CI 
2.08–2.11). The incidence of first-time MI decreased with increasing level of 
education in both sexes and regardless of country of birth. A higher incidence 
was found among individuals with less than 9 years of education compared to 
those with more than 12 years of education. The incidence was 50–85% higher 
in the group with the least education irrespective of sex and birth country. The 
increased risk by education level remained stronger among women but was more 
pronounced in Sweden-born (IRR 1.85, 95% CI 1.81–1.89) than foreign-born 
individuals (IRR 1.77, 95% CI 1.67–1.87). Regardless of country of birth, 
comorbidities were associated with increased risk of first-time MI. However, the 
association between history of hypertension or diabetes and first-time MI was 
more pronounced among foreign-born than Sweden-born individuals of both 
sexes (see Paper I). Age-standardized rates were higher in men than women as 
well as in stratified analysis by country of birth. The trend based on jointpoint 
regression analyses during the study period, between 1987 and 2008, was more 
prominent among Sweden-born (men: APC -2.1, p<0.0001 and women: APC -
1.0, p<0.0001) than foreign-born individuals (men: APC -1.2, p<0.0001 and 
women: APC -0.4, p=0.05) (see Paper I). However, temporary increases in age-
standardized rates for both sexes were found around the year 2001 (see Paper I). 
At the country level and compared with Sweden-born individuals, men and 
women from Western Asia, Europe, Northern and Eastern Europe showed high 
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incidence of first-time MI. Men born in Southern and Western Asia had a 50% 
(95% CI 40–60%) higher risk than men born in Sweden.  By contrast, men and 
women from Eastern Africa, South-Eastern Asia, Western Europe and Latin 
America showed lower first-time MI incidence. We observed the highest 3- and 
4-fold significant increased risk among men born in Bangladesh and Armenia, 
respectively, after multivariable adjustment. The lowest MI incidence rate 
decreases of about 50% and 70% were found among men born in Japan and 
Bolivia, respectively.  The highest incidences were found among women born in 
Pakistan and Afghanistan (2-fold increase) and in Serbia (4-fold increase) 
compared to Sweden-born women. The lowest incidences were found in women 
born in Morocco, Somalia, Japan and China (decreased by 40–60% compared to 
Sweden-born women).  
Mortality after day 28 
During the study (1987–2008) there were 37,416 and 25,122 cases of MI-
specific deaths among men and women, respectively. A downward trend in 
mortality risk was found throughout this period. Regardless of sex and country 
of birth, MI patients with a low level of education had around 50% statistically 
significantly worse prognosis compared with those with more than 12 years of 
education. We observed a 15% higher case fatality after day 28 among men than 
women (HR 1.15, 95% CI 1.13–1.17). We found the same association between 
high levels of education and estimated case fatality after day 28 due to IHD, and 
to a lesser degree due to any cause. We also found a negative association 
between case fatality and diabetes. In addition, an improvement was detected 
regarding mortality after MI during the study period.  
6.2 STUDY II 
Recommended drug use after acute myocardial infarction by Migration status 
and educational level 
Aim:  
To investigate cardiovascular drug use after first MI in relation to country of 
birth, SEP, gender, age and drugs used before MI 
The study comprised 4782 foreign-born and 32,788 Sweden-born patients. There 
was no apparent significant difference in drug use after MI between foreign-born 
and Sweden-born patients after taking into consideration drugs used prior to MI 
and adjustment for age, sex, marital status and education. Among those who did 
not take any cardiovascular drugs before MI, there were no differences in drug 
use after MI by migration status (OR 1.00, 95% CI 0.89–1.12). Among those 
who took some but not all recommended cardiovascular drugs before MI, 
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foreign-born cases had a slightly lower but non-significant use of recommended 
drugs in the adjusted model (OR 0.92, 95% CI 0.83–1.03). Although not 
statistically significant, but there was a slight tendency towards lower use of 
recommended drugs after MI in patients from Nordic, EU and other European 
countries as well as outside Europe compared with Sweden-born patients in the 
crude and adjusted models. We conducted a stratified analysis by country of 
birth to determine the effect of education on drug use after MI among Sweden-
born and foreign-born groups separately. Neither Sweden-born nor foreign-born 
men showed any educational differences in recommended drug use after MI. 
However, poorly educated women, regardless of country of birth, used fewer 
recommended drugs after MI. In Sweden-born women, drug use was lower in 
patients with unknown, lower and middle education levels compared to those 
with the highest level of education (OR 0.62, 95% CI 0.46–0.83; OR 0.85, 95% 
CI 0.74–0.96; and OR 0.82, 95% CI 0.71–0.95, respectively). The corresponding 
values for foreign-born women were: OR 0.72, 95% CI 0.44–1.19; OR 0.51, 
95% CI 0.34–0.77; and OR 0.65, 95% CI 0.42–1.00. Among those treated with 
some but not all recommended cardiovascular drugs before MI, we found a non-
significant slightly lower use of drugs after MI among foreign-born compared to 
Sweden-born patients (men: OR 0.89, 95% CI 0.77–1.04; women: OR 0.96, 95% 
CI 0.82–1.12). Among those who did not use cardiovascular drugs before MI, 
we found a non-significant slightly lower use of drugs after MI among foreign-
born men compared to Sweden-born men (OR 0.94, 95% CI 0.81–1.09). In the 
stratified analysis by education level, and after adjustment for age, sex, diabetes 
and marital status, we compared foreign-born to Sweden-born individuals. In the 
group with shorter duration of education, those born outside Sweden had a lower 
use of recommended drugs after MI among those with some but not all 
recommended cardiovascular drugs before MI (OR 0.82, 95% CI 0.70–0.96). 
6.3  STUDY III 
Downward trend in the risk of second myocardial infarction in Sweden, 1987-
2007: breakdown by socioeconomic position, gender, and country of birth 
Aim: 
To evaluate the risk and trend of recurrent MI in Sweden in relation to country 
of birth, SEP, gender and age 
To determine the effect of duration of residence and age at immigration on 
recurrence of MI 
During the study period (1987–2007), we detected 117,679 fatal and non-fatal 
cases of second MI of which 3670 and 6151 were among women and men born 
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outside Sweden, respectively. In both sexes and regardless of country of birth, a 
decreasing trend towards increased risk of second MI was observed. The risk of 
second MI was 14% higher among men than women in the adjusted model as 
well as in the stratified analysis by country of birth. A small increase in risk of 
second MI was found among immigrants compared with Sweden-born patients: 
HR 1.07, 95% CI 1.04–1.10 and HR 1.05, 95% CI 1.02–1.09 in both men and 
women, respectively. In both Sweden-born and foreign-born patients who had  
less than 9 years of education, women had a 36% and 54% higher risk, 
respectively, compared to those with the highest attained level of education. The 
corresponding increase risks were 29% and 30% among Sweden-born and 
foreign-born men (see Paper III). During the study period, the risk of second MI 
correlated negatively with calendar year of first MI. Men born in different world 
regions, continents and regions had either similar or higher risks of second MI 
than men born in Sweden. The highest risks were found among women born in 
Northern Africa (HR 2.06, 95% CI 1.07–3.97) and Western Asia (HR 1.35, 95% 
CI 1.16–1.57). Women born in India (HR 1.84, 95% CI 1.02–3.33), Lebanon 
(HR 1.68, 95% CI 1.10–2.55) and Palestine (HR 2.50, 95% CI 1.24–5.00) had 
the highest risk. Men born in Western Europe and in the Netherlands had the 
lowest statically significant risk (HR 0.90, 95% CI 0.82–0.98 and HR 0.65, 95% 
CI 0.44–0.94, respectively). Among the African regions, men born in Uganda, 
Algeria and Tunisia had the highest risk (more than a 2-fold increase) and among 
the Asian regions men born in Palestine had the highest risk (more than 60% 
increase) compared to Sweden-born men. We found a positive correlation 
between the risk of second MI and age at the time of immigration for men, and a 
negative association with length of residence for both women (HR 1.20, 95% CI 
1.08–1.34) and men (HR 1.17, 95% CI 1.08–1.26). 
6.4 STUDY IV 
Short and long term mortality after coronary artery bypass grafting (CABG) 
is influenced by socioeconomic position but not by migration status in 
Sweden, 1995-2007  
Aim: 
To study mortality after CABG in relation to country of birth, SEP, gender and 
age  
During the study period (1995–2007), we documented 15,284 deaths among 
72,333 patients who underwent a first isolated CABG. About 10.4% of deaths 
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occurred among foreign-born patients. Overall, men had a statistically 
significantly higher mortality risk than women after multivariable adjustment 
(HR 1.14, 95% CI 1.10–1.18). Regardless of country of birth and sex, patients 
with a low level of education had a statistically significantly higher mortality risk 
compared with those with longer than 12 years of education. This finding was 
more pronounced among foreign-born women (HR 1.53, 95% CI 1.00–2.33) (see 
Paper IV). There were no significant differences in the risk of early or late 
mortality after CABG between foreign-born and Sweden-born men and women 
throughout the study period after multivariable adjustment. There was a slight 
improvement in overall survival among foreign-born compared to Sweden-born 
men and women. Patients with diabetes or with missing information regarding 
diabetes had higher mortality than patients without diabetes (foreign-born men: 
HR 1.60, 95% CI 1.40–1.84; Sweden-born men: HR 1.64, 95% CI 1.56–1.72; 
foreign-born women: HR 1.53, 95% CI 1.24–1.88; Sweden-born women: HR 
1.84, 95% CI 1.70–1.99). We found higher mortality after CABG among men 
born in Europe, Southern Europe, Eastern Asia and Eastern Africa compared 
with Sweden-born men and women. By contrast, men born in Asia and South-
Central Asia, showed lower risks compared with Sweden-born patients. 
However, we found higher mortality risks among men born in Denmark, Bosnia 
and Chile, and both men and women born in China. Men born in Iran had a 
lower mortality risk compared with men born in Sweden. The highest risks were 
found in men born in Eastern Africa (HR 3.80, 95% CI 1.58–9.17), China (HR 
3.61, 95% CI 1.50–8.69) and Chile (HR 2.12, 95% CI 1.01–4.47). 
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7 METHODOLOGICAL CONSIDERATIONS 
7.1 STRENGTHS AND LIMITATIONS 
All Studies are cohort studies based on national registers with high quality and 
validity. Strengths of the studies include the cohort design, the large sample size, 
and the complete nationwide coverage of incident cases of MI and of study 
exposures (country of birth and education level) and outcomes (incident cases of 
first and second MI, mortality of patients undergoing CABG and filled 
prescriptions after MI) and virtually complete follow-up. 
Reliable demographic information about important lifestyle risk factors was 
lacking (all studies). This is a limitation as differences in risk profile between 
foreign-born and Sweden-born patients, such as higher prevalence of smoking 
and physical inactivity, have been observed (49, 207). There were insufficient 
numbers of observations for valid analyses regarding body mass index, 
conditions such as left ventricular function, number of diseased vessels, 
completeness of revascularization, indication for surgery and repeat 
revascularization (Study IV). Furthermore medical management after hospital 
discharge was not known (Study IV). 
We did not classify foreign-born as either refugees or labour immigrants, which 
is a limitation in all studies. It has been shown that refugees have a higher risk of 
cardiovascular mortality compared to labour immigrants (208).   
7.1.1 Misclassification of exposure  
7.1.1.1 Country of birth 
We do not suspect any major misclassification of country of birth due to recall 
bias as the register-based cohort design eliminates such bias. However, there 
could be some misclassification of country of birth as asylum seekers might be 
likely to state a country of origin for which the chance of being approved for 
immigration is high. However, we do not believe that this potential 
misclassification would affect our results to any great extent. 
7.1.1.2 Ethnicity 
In our studiess we used country of birth (migration status) not ethnicity. It is 
fobidden in Sweden to record ethnicity as it is considered as a sensitive issue. 
To use ethnicity or country of birth may be depend on the type of research 
question. For example ethnicity has been recommended for studying mental 
health among foreign-born. Anna-Clara Hollander explained that ‘’due to the 
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cultural aspects of mental health, country or area of origin is harder to 
interprit’’ (31). A problem when using country of birth is that  one country may 
include several ethnic groups and one ethnic group maybe presented in several 
countries. For example Kurdish people and Assyrians are distributed in several 
countries like Iraq, Iran, Syria and Turkey. They differ from other groups in 
these countries in many aspects including diet, cultural attitudes, and lifestyle. 
A study about caner and migration in Sweden  has mentioned that ethnicity 
referes to a complex phenomena including both subjective and objective 
criteria it might be both theoretically and practically difficult to measure. 
Hence, the author has used country of birth and acknowledge the difficulties in 
measuring ethnicity (191). 
7.1.1.3 Education level 
However, we suspect some misclassification among foreign-born 
participants. According to our classification and Swedish standards, individuals 
with only compulsory school education are regarded as having a low level of 
education. However, in many countries having 9 years of schooling is regarded 
as having a high level of education. Depending on whether education is seen as a 
measure of SEP on a relative scale of social status or as a proxy for intellectual 
capacity, this could be seen as an underestimation of the education level. In this 
case the errors will be in one direction, i.e. highly educated persons would be 
classified as being less well educated. This could affect the comparison in the 
stratified analyses between foreign-born and Swedish-born individuals with a 
low education level. The foreign-born group should thus be regarded as better 
educated and hence are likely to have better health. It is however difficult to 
speculate on the magnitude if this problem. 
7.1.2 Precision  
The studies have high statistical precision because of their large sample size and 
long and virtually complete follow-up. We had enough power to stratify the 
analysis by age at immigration and duration of residence (Study III). This 
increased the opportunity to explore the effect of migration on health. However, 
some information on date of immigration was missing. Overall there was 12% 
missing information on date of immigration which varied considerably by 
country of birth ranging from less than 5% to 67%. The lowest level of missing 
information was  found among those born in Latin America and Asia and the 
highest level was among those born in Estonia (191). We analysed duration of 
residence and age at immigration only among immigrants with a known 
immigration date; however, we do not believe that these missing data would 
affect our results. In our analysis of recurrent MI, mortality after CABG and drug 
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use after first MI we followed individuals to the date of death, date of emigration 
or end of study. However, it is possible that foreign-born individuals may return 
to their country of origin during the time of follow-up without reporting this to 
the Swedish authorities. Hence, we anticipate the slight underestimation of the 
risk of outcome to be greater among those born outside than among those born 
within Sweden. 
7.1.3 Misclassification of outcome 
We lacked information about history of previous MI events among foreign-born 
subjects and among those born in Sweden if the events occurred outside of 
Sweden. Thus, we assumed that the first record of MI in the NPR or the Causes 
of Death Register was the first MI. Hence, we might have misclassified some 
second MIs as first MIs, mostly among foreign-born patients. Likewise, some 
MIs that were regarded as second MIs could actually have been third MIs. Case 
fatality is higher after second MI than after first MI (209), and the risk of another 
MI is higher after the second MI than after the first MI (209). The risk of another 
MI is higher after the second MI than after the first (209). Therefore, this 
potential misclassification might induce an overestimation of the case fatality 
after first MI foremost among foreign-born individuals (Study I) as well as an 
overestimation of the risk of second MI among these patients (Study III). 
However, we addressed this issue (Study I) by investigating MI incidence and 
case fatality after MI after restricting the analyses to those free of MI for at least 
8 years prior to the MI (210). The risk estimates for foreign-born and Sweden-
born patients were similar regardless of which criteria for first MI were used. 
Furthermore, we lacked information about clinical data, such as severity and site 
of infarction (Study I and III), as well as medical treatment after first MI, which 
could have underestimated our results (Studies I and III). 
7.2 BIAS ANDCONFOUNDING 
True association, confounding, bias, chance and reverse causation 
Generally in all epidemiological studies you either find an 
association or not. Either the association is a true association between exposure 
and outcome or it may be explained by confounding, bias or chance, or by 
reverse causality. 
Regarding the concept of chance (that the detected association is simply due to 
chance) we have computed a CI to determine where the “real” measure of a 
result is likely to lie (i.e. the true HR and OR). We did not have to consider the 
problem of reverse causation (by which instead of the exposure causing the 
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outcome, the outcome in fact caused the exposure) between the outcome and the 
exposure, as our exposure was country of birth. 
Confounding 
For a variable to be a confounder it must be related to the exposure 
of interest and it must be independently associated with the outcome. 
                   Exposure                                                 outcome  
 
 
                                                 Confounder 
The confounder can change the result and the direction of the association. 
Confounding may cause a positive association between the exposure and the 
outcome, or vice versa. The most common confounders in epidemiology are 
non-modifiable variables such as age and sex and modifiable variables such as 
diet, smoking habit and SEP. There are different approaches to control for 
confounding in epidemiological studies. For example, confounders can be 
controlled for in the study design phase by matching, restriction or 
randomization, whereas it can be controlled for in the analysis phase by 
stratification and multivariable adjustment. In the analysis phase of our studies 
we have controlled for confounders by stratification and multivariable analysis. 
Stratification is a commonly used method in which the analysis is performed and 
a measure of outcome is calculated separately for each level of the potential 
confounder. For example, we have stratified for sex in the analysis and adjusted 
for potential confounders in the multivariable adjusted models 
Bias  
Bias is a systematic error in an estimate (i.e. the results will be either above or 
below the true value), and the result of defects in the study design. Bias cannot 
be controlled for in the analysis. If the finding and the association results from 
bias, the finding is simply wrong. 
Selection bias and information bias: these are two main forms of bias in 
epidemiological studies. Selection bias occurs when an unrepresentative 
population is selected during sampling of the study population. Non-response is 
a type of selection bias; for example, patients with the disease of interest may be 
more likely to respond because of their interest in the study results, or in some 
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circumstances they may be less likely to participate because of poor health. This 
type of selection bias is more common in case–control studies. By contrast, loss 
to follow-up is another type of selection bias which can be an issue for cohort 
studies; participants may drop out for a variety of reasons which could possibly 
bias results if the reason for leaving the study is related to the exposure or 
outcome of interest. We have considered this issue in our follow-up period in the 
design phase and in the analysis phase (see methodology section). Information 
bias occurs when information is collected incorrectly or inaccurately. This may 
result in either misclassification of outcome or exposure. Recall bias is mainly a 
problem in case–control studies, when cases may recall their exposure more 
completely than control subjects. We did not have a problem with recall bias in 
our studies. 
Selection bias is not a common problem for cohort-based studies. To elucidate 
the selection bias in the current studies we should mention that migration is not a 
random process.  Emigrants are usually self-selected from the population of their 
birth countries. They are from specific ethnic groups with particular 
socioeconomic and religious backgrounds but being healthy can also be an 
important factor for migration: the “healthy migrant effect” (211-214). Indeed, 
emigrants are often healthier than the general population that stays behind in the 
country of origin.  
Migration is a complex process with different related reasons for migration. In 
general, leaving the home country and moving to new country demands 
considerable resources. The reasons for migration, such as health, family, 
occupation, education and whether or not the immigrant is a refugee have an 
impact on health. It is common to find a higher proportion of individuals with 
higher attained level of education among immigrants (215). The “healthy 
migrant effect” has been shown in studies of death among Turkish immigrants in 
Germany with lower mortality than that of native Germans (46, 55). It has been 
suggested that comparison should be made between immigrants and the 
population from their home country to study the effect of selection bias. 
However, this is not usually possible. 
Additional points related to bias and confounding  
We stratified analyses by migration status to compare some exposure for 
example education among immigrant groups and Swedes. We found the same 
effect of education regardless of country of birth but we did not have access to 
data for comparison with the population in the country of origin.  
The age distribution is usually varied between different countries in the world as 
was the case for immigrant and Swedish-born populations in our studies. For that 
reason we have adjusted for age in all models. We have also used an age-
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standardization method with the world population as the standard to adjust only 
for age. 
In addition the trend in incidence of disease and the risk of outcomes vary among 
immigrants and the host population over time. Therefore we adjusted for 
calendar year (Studies I, III and IV). We used education as a proxy for SEP as 
we believe that SEP is one of the determinants of disease. We have adjusted for 
and stratified analyses by SEP.  
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8 DISCUSSION 
8.1 MAIN FINDINGS  
In this nationwide project from Sweden, we found that incidence of and 
mortality after first time MI (Study I), drug use after MI (Study II), recurrent MI 
(Study III) and mortality after CABG (Study IV) were influenced by country of 
birth (Studies I and III) and SEP. The aim of this thesis was to increase 
understanding of migration status and CHD incidence (Study I), outcome and 
prognosis (Studies I, III and IV) and management (study II, and IV). We 
explored the above measures in the Swedish total population with detailed 
information on individual country of birth.   
this project is novel in that we found a less pronounced decreasing trend of first-
time MI incidence among women and foreign-born individual (Study I), with no 
differences in drug use after MI (Study II) and mortality after CABG (Study IV). 
To the best of our knowledge our finding of a downward trend of second MI in 
Sweden is new. The risk of second MI in Sweden has not been explored 
previously with detailed information about country of birth. We found a higher 
risk of recurrent MI among men compared to women regardless of country of 
birth. The finding of a higher risk of second MI among foreign-born compared to 
Sweden born patients was also new. Furthermore a higher age-standardized rate 
of MI was found among immigrants in Sweden. In addition, among immigrant, 
we observed that the risk of second MI was modified by age at immigration and 
time spent in Sweden. 
8.2 INTERPRETATION OF FINDINGS 
8.3 MIGRATION STATUS 
The higher incidence and worse outcome of MI among immigrants may partly 
be explained by the differences in lifestyle factors between immigrants and 
native Swedes. Along with access to appropriate medical treatment, 
environmental factors are also important for prognosis after MI. For example, 
a higher prevalence of smoking and physical inactivity, has been observed 
previously, which might explain some of the increased risk found among 
certain groups of immigrants in our study (49, 207, 216, 217). In particular, a 
high prevalence of physical inactivity among immigrant women has been 
shown (49, 217, 218). Previous studies have found differences in risk factor 
patterns of CHD between immigrants in Sweden (11, 207, 219). A higher 
prevalence of hypertension and the highest mean cholesterol values were 
found among Finnish immigrants in Sweden (207, 220). Finnish and Turkish 
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immigrants have the highest age-adjusted risk of diabetes (11, 49). A higher 
prevalence of obesity among women born in Turkey, Iraq, Bosnia, Finland, 
South Europe, Chile and South America compared to women born in Sweden 
has been  reported previously (191, 221, 222). Furthermore, migration itself is 
a stressful process, with individuals subject to many pressures and anxiety. It 
has been highlighted that migration can have a negative influence on 
immigrant health, especially with regard to anxiety and depression (50, 51). 
The higher incidence of first-time MI among some immigrants in Sweden is 
likely to partly be explained by severe mental stress such as post-traumatic 
stress disorder among those born in Serbia and Bosnia (53). After the Bosnian 
civil war, a large number of refuges came to Sweden, and a high prevalence of 
common anxiety disorders, as well as post-traumatic stress disorder have been 
reported among immigrants born in Serbia and Bosnia. 
The migration process (223) involves many changes such as separation from 
friends and relatives, language, culture, contact and loss of social status (38) 
which may cause migration stress that influences health behaviours (e.g. 
physical inactivity, smoking and obesity) as well as  CHD  risk factors (e.g. 
high cholesterol, diabetes and hypertension) (49, 207). In addition, the 
incidence of CHD depends on the country of origin (52). Immigrants born in 
Europe had a very similar incidence of MI compared with native Swedes. This 
could in part be due to similarities in lifestyle factors and that immigrants from 
Europe may cope with a new life in Sweden more easily than non-European 
immigrants, as they might better understand the Swedish culture, norms and 
society. All this could lead to a better integration with less stress. 
In some settings it has been shown that emigrants are a selected group who are 
healthier than who stay behind in the country of origin (46, 54, 55). In general, 
immigrants are made up of a mixed group of different population subgroups 
depending on the countries of origin as well as subjects with different reasons for 
immigration. With regard to the “healthy migrant effect”, immigrants may have 
a lower risk and incidence of MI than people in the host country. However 
because in general migration is a stressful process, a higher incidence and risk of 
MI among immigrants might be expected. In both cases, from an equity 
perspective, we should aim to minimizing the differences between immigrants 
and host populations and further try to decrease the incidence of MI for the 
whole population. Therefore our findings of a difference, albeit small, in CHD 
outcomes between immigrants overall compared to Swedes but still of value for 
the Swedish health care system. We did not compare the incidence and outcome 
of CHD between immigrants in Sweden to those who stayed behind in their 
country of origin. However, a majority of immigrants in Sweden have been 
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found to have better outcome of CHD compared to those in their country of birth 
(47).  
In addition, moving to a new social and cultural environment may modify the 
behaviour and CHD risk factors that the immigrant brings from the country of 
birth. A favourable adoption process to the Swedish dietary habits after 
migration among Iranians living in Sweden was found compared to Iranians 
living in Iran (224). In another study it was found that migration from Finland to 
Sweden was associated with adopting new healthy dietary habits, but on the 
other hand  losing other healthy dietary habits (225). We explored the effect of 
acculturation by studying the risk of second MI by age at the time of 
immigration and length of stay in Sweden. The lower risk of second MI among 
immigrants with longer duration of residence in Sweden observed in our study 
may reflect multiple factors, such as better command of the Swedish language 
with corresponding increased trust in, knowledge of and utilization of the 
healthcare system and improved compliance with medical interventions, 
including pharmacotherapies, smoking cessation dietary interventions and other 
treatment programs. The positive effect of length of stay has previously been 
investigated with regard to the risk of first MI among immigrants living in 
Sweden (8). Our findings of a downward trend in case fatality after first MI and 
risk of second MI over the last two decades among immigrant in Sweden is in 
line with observations in the Northern Sweden MONICA study from 1985 to 
1998 (226) and in the total Swedish population up to 2001(226, 227) as well as 
in Finland (228, 229). The finding is partly due to better primary and secondary 
prevention (229).  
Instead of finding that neither short-nor long-term mortality after CABG was 
influenced by migration status in Sweden we would probably see to a lower risk 
among immigrants if were able to adjust for unmeasured life style factors such as 
smoking as we expect smoking, to be more common among foreign-born than 
among Sweden-born men (49, 207). We found no significant differences in drug 
use after MI by migration status in contrast to the findings of one recent study of 
lower use among foreign-born individuals (27). However, the authors did not 
take into account drug use before MI; hence our study is not confounded by 
access to primary prevention.  In addition, we investigated the combination of 
recommended drugs after MI not only single drug use.   
That we found no differences in drug use after MI or in mortality after CABG 
could party be explained by the universal Swedish health system and by the fact 
Sweden is a welfare state with relatively low health inequity (230, 231). But the 
finding of equal drug use still may not reflect health equity and equality in access 
to health care in Sweden. If we expect some immigrant groups to have a higher 
prevalence of hypertension and hypercholesterolaemia (207, 220), greater use of 
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ACE inhibitors and lipid-lowering agents would be predicted in Finnish 
immigrants compared to Swedish-born individuals 
8.4 SEP AND GENDER  
The inverse association between SEP and MI incidence,  risk of second MI and 
CABG mortality are in line with the findings of other studies (14, 15, 19, 22, 67-
74, 84, 91, 210, 232-236). Similarly, in line with our results, studies have shown 
under-prescription of drugs in lower SEP groups in Sweden and worldwide (25, 
27, 67-74, 237, 238). Women and immigrants with low SEP had a higher risk of 
second MI (Study III). This impact of education could possibly  be explained by 
the effect of lower use of medication (24, 27, 239) and access to 
revascularization procedures (86, 240). Furthermore, patients with a low SEP 
may be less likely to agree to cardiac interventions (241). Also, the prevalence of 
high cholesterol, hypertension, smoking, and other classical MI risk factors is 
higher in individuals with a low SEP (87-89).  
The incidence of MI continues to decrease in both sexes regardless of country of 
birth. Recently, among women, the risk has been decreasing at a slower rate than 
for men. The prevalence of smoking may explain this observation. Smoking has 
historically been higher in men than women (89) but this seems to be changing 
towards  higher prevalence in women and decreasing prevalence in men (199). 
We observed a slight increase in first-time MI incidence around the year 2001. 
The change in incidence can be explained by the change in diagnostic criteria of 
MI introduced in 2000. The new criteria have focused on troponin T 
concentrations combined with other factors. According to the new criteria of MI 
in 2000, cases with acute coronary syndrome that had been diagnosed as having 
unstable angina are now categorized as having myocardial infarction (242). 
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9 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
 Our finding of inequalities in incidence of MI and health outcome after 
MI (second MI) by country of birth is in accordance with the results of 
the majority of previous studies in Sweden. Poor coronary heart disease 
(CHD) health was found among some groups of immigrants, in particular 
among foreign-born women. Hence, public health policy should focus 
more on the health of migrants. Furthermore, immigrants with the highest 
risk of disease and poor health outcome should be targeted. 
 The risk of a second MI among immigrants tended to be more similar to 
that among Sweden born. Such observations gives a hint on the 
environmental influence on the CHD risk. Our findings support the 
hypothesis that acculturation measured by the time spent in the host 
country may have a positive influence on immigrant health (given the 
incidence in the host country is lower than in the country of origin) 
 Our findings do not support those of previous studies showing that drug 
consumption after MI is influenced by country of birth in Sweden. 
However detailed information about indications for medication, 
comorbidities and risk factors among individuals is necessary in order 
evaluate health equity with regards to drug consumption after MI. 
 Our findings support the idea that universal health insurance and 
coverage has a positive impact on diseases and health outcomes. No 
difference in early and late mortality after CABG was found between 
immigrants and Sweden-born patients. However, further research is 
needed to include more information regarding severity of disease, 
comorbidities and risk factors. 
 Despite the decreasing trend in incidence of CHD and improvement in 
the prognosis and management, a low level of education as a measure of 
poor SEP remains an important risk indicator for all outcomes in our 
study. This needs further investigation. 
 The concepts of migration, SEP and gender are complementary to each 
other. Research regarding migration and health is not complete without 
considering each of these factors. 
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11 SAMMANFATTNING PÅ SVENSKA/ SUMMARY 
IN SWEDISH 
Bakgrund: Hjärt-kärlsjukdom med framförallt akut hjärtinfarkt är en av de stora folksjukdomarna. I Sverige 
står cirkulationsorganens sjukdomar för cirka 50 procent av all dödlighet varav hälften är hjärtsjukdom. 
Ungefär 16 procent av befolkningen i Sverige är utlandsfödd. Etniska skillnader i sjukdomsförekomst och 
prognos efter sjukdom har visats förekomma i stora delar av världen. Syftet med denna avhandling är att öka 
kunskapen om skillnader i sjukvårdsutnyttjande efter hjärtsjukdom genom att studera insjuknande och 
återinsjuknande i hjärtinfarkt, läkemedelsanvändning efter hjärtinfarkt, och prognos efter hjärtinfarkt och 
efter by-pass-operation i relation till födelseland, socioekonomisk position och kön. 
Material och metod: Det material som används är en sammaställd databas för att studera hälsoläget hos 
invandrare i Sverige. Den så kallade Migration och Hälsa-databasen är en samkörning mellan ett stort antal 
nationella register. Studieperioderna var 1987-2008 (Studie I), 2006-2008 (Studie II), 1987-2007 (Studie III), 
och 1995-2007 (Studie IV). Studiepopulationen var totalbefolkningen (Studie I), alla 
förstagångshjärtinfarkter (Studie I, II och III) samt alla förstagångs by-pass-opererade (Studie IV). De utfall 
som studerats var insjuknande och dödlighet efter hjärtinfarkt, läkemedelsanvändning efter hjärtinfarkt, 
återinsjuknande i hjärtinfarkt, och dödlighet efter by-pass-operation. Potentiella störfaktorer var ålder, kön, 
utbildningsnivå, samsjuklighet, kalenderår, civilstånd och väntetid inför operation. Vi beräknande 
incidensrat (IRR), hazard ratio (HR) (Studie I, III, IV) och oddskvot (OR) (Studie II) med 95 procentiga 
konfidensintervall (95 % CI) i multivariata modeller genom Poisson, Cox, och logistisk regression. 
Resultat: En nedåtgående trend i insjuknande i förstagångshjärtinfarkt och i dödlighet efter 28 dagar i 
hjärtinfarkt sågs för båda könen oavsett födelseland. Dock var minskningen över tid något större för kvinnor 
och för utlandsfödda. Bland de som inte hade adekvat hjärtmedicinering innan hjärtinfarkt hade utlandsfödda 
något mindre användning av rekommenderade läkemedel efter hjärtinfarkt i den justerade modellen (OR 
0,92 95 % CI 0,83–1,03). Bland de med lägst utbildningsnivå hade utlandsfödda något lägre användning av 
rekommenderade läkemedel jämfört med svenskfödda. Kvinnor med låg socioekonomisk position hade lägre 
användning av läkemedel jämfört med män oberoende av födelseland (Studie II). En nedåtgående trend i 
risken att återinsjukna i hjärtinfarkt observerades.  Män hade oberoende av födelseland en högre risk för 
återinsjuknande i hjärtinfarkt än kvinnor (HR 1,14 95 % CI 1,12- 1,55). Utlandsfödda hade en något högre 
risk än svenskfödda. Utlandsfödda som bott i Sverige kortare än 35 år hade en högre risk än de som bott 
längre än 35 år (Studie III). Vare sig bland män eller bland kvinnor var det någon skillnad mellan 
utlandsfödda eller svenskfödda i dödlighet på kort eller lång sikt efter by-pass-operation. Dock skilde sig 
dödligheten åt mellan födelseland och var högst för födda i östra Afrika (HR 3,80 95 % CI 1,58–9,17), Kina 
(HR 3,61 95 % CI 1,50–8,59), och Chile (HR 2,12 95 % CI 1,01–4,47). Patienter med låg utbildningsnivå 
hade högre insjuknande i hjärtinfarkt och sämre prognos efter hjärtinfarkt och by-pass-operation jämfört med 
de med utbildning längre än 12 år oberoende av kön och födelseland (Studie I, III, och IV). Denna skillnad 
var tydligare bland utlandsfödda kvinnor. 
Slutsats: En något ökad risk för insjuknande i och dödlighet efter förstagångshjärtinfarkt och en ökad risk 
för återinsjuknande i hjärtinfarkt sågs hos utlandsfödda jämfört med svenskfödda. Även om insjuknande och 
dödlighet efter förstagångshjärtinfarkt och risk för återinsjuknande i hjärtinfarkt har fortsatt att minska över 
tid så har de med låg socioekonomisk position, mätt som låg utbildningsnivå, oberoende av födelseland och 
kön alltjämt en ökad risk för dessa händelser. Ingen uppenbar skillnad mellan utlandsfödda och svenskfödda 
i användning av rekommenderade läkemedel efter hjärtinfarkt kunde ses. Det var ingen skillnad i dödlighet 
vare sig på kort eller på långsikt efter by-pass-operation mellan utlandsfödda och svenskfödda. Dock visar 
skillnaderna i adekvat sekundärprevention efter hjärtinfarkt på ojämlikhet i vård mellan personer med olika 
utbildningsnivå oberoende av födelseland. 
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12 PUXTE/ SUMMARY IN KURDISH 
Nexoşî dil w lulekanî xwén (cardiovascular diease CVD) kéşeîekî serekî biwarî 
tendirustîye le cîhanda. Be péyî raportî salaneî rékxirawî tendirustî cîhanî (WHO), le salî 2010 nizîkeî 17 
milîon  mirdin tomar kirawe be hokarî nexoşîyekanî  dil (CVD), le néwan ew mirdwaneşda nizîkeî 7 milîon 
hokarî mirdinyan nexoşî lule xwénberakanî koronerî biwe, wate nexosî ew xwénberaneî ke xwén bo dil 
deben (Coronory heart disease, CHD). Cégeî amaje pé kirdine ke le wilatî Swîd, salane réjeyekî zor le 
serheldanî (Incidence) nexoşîyekanî dil, w mirdin (Mortality) be hokarî nexoşî dil tomar dekrét. Be şéweyekî 
giştî rudanî nexoşî celdeî dil (Myocardial infarction, MI), le hemu corekanî nexoşî dil bawtire le néwan 
mirovî pègeîşhtu (Adult). 
Dil weku hemu endamekanî tirî leş péwîstî be xwén w oxigîn heye. Katék xwén be şéweîekî asaîy nagate 
masulkekanî dil, ewa mirov tuşî nîşanekanî nexoşî dil debét. Le ruî zanistî şanezanîyewe hokarekanî 
degretewe bo kelekebunî çewrî w rîşalî faîbrîn le naw lule xwénekani koronerîda yan piçranî (rupture) ew 
girmoleî (Atherosclerotic plaque) ke dirust buwe ke lewaneye bibéte serheldanî celdeî dil yan bibéte hoy 
mirdinî nexoşe tuşbuweke. 
Hokarekanî nexoşî dil ewaneî taku ésta zanrabin bo nimune: (temen, hokarî bomaweyî, regez w nejad), em 
hokarane hokarî negorin.  Hokarekanî dike be hokare gorawekan denasrén çunke mirov ta radeyek detwanè 
beseryanda zal bét, bo nimune: (pestanî xwén, çewrî, cigerekéşan, nexoşî şekre, qelewî w werjiş nekirdin e 
legel hokare derunîekan). 
Be péî twéjinewe zanistîyekan be şéweyekî  giştî réjeî tuşbun be nexoşîyekanî dil le néw penahendekanda 
(Immigrants) ziyatire be berawerd legel ewaneî le dayik buî wilateken. Wek zanirawe réjeyekî zor le xelkî le 
dayikbuî dereweî wilat (Foreign-born) le wilatî Swîd dejîn ke réjeyan degate nizîkeî (16 %) î komelgeî Swîd.  
Ème le wilatî Swîd le zankoî Karolinska (Karolinska Institutet), wek çend twéjerék le biwarî pizîşkî 
nexoşîyekanî dil, lèkolîneweman le ser le dayikbuwanî dereweî wilat ke le Swîd dejîn encam da. Le encam 
da, boman derkewt ke réjeî rudanî nexoşî celdeî dil be şèweyekî giştî ruî le kembun daye le néwan ewaneî le 
Swîd le dayikbun w le dayikbuwanî dereweî Swîd. Belam em diyardeî kem bunewe kemtir bedî dekrét 
lenéwan xanime le dayikbuwekanî dereweî Swîd. Egerî rudanî celdeî dil (MI) w dubare buneweî (second 
attack of MI) le néwan le dayikbuwanî dereweî wilat zîatire be berawerd legel ewaneî le Swîd le dayik bun. 
Paş twéjîneweî zîatir boman derkewt ke egerî mirdin le dwaî encamdanî neştergerî xwènberekanî koronerî 
(coronary artery bypass graft) hiç cîawazîyekman bedî nekird le néwan le dayikbuwanî nawewe w le 
dayikbuwanî dereweî Swîd, herweha réjeî wergirtinî derman w çareser cîawaz nebun le nèwan ew du 
girupeda. Legel eweş da le hemu twéjînewekanda boman derkewt ke ewaneî ast w pileî xwèndinîan nizme 
zîatir tuşî ew nexoşîyane debin. Herwaha egerî mirdin be hoy nexoşîyekanî dil w neştergerî péwend bew 
nexoşîyane le néwanyanda zîatire. Sereraî eweş be réjeyekî kemtir çareser w derman wer degrin bo ew 
nexoşiyane be berawerd le gel ewaneî ke pileî xwéndewarîyan berz tire. 
Zanîn w peîrew kirdinî rénimaîye tendirustîyekan be hengawékî giring dadenrét bo xo parastin le tuşbun w 
egerî mirdin bem nexoşîye. Encamekanî em twéjîneweye agadarkirdineweyeke bo hawwilatîyanî le dayikbuî 
dereweî Swîd w herweha bo sîstemi tendirustî Swîd. Lékolîneweî zîatir péwîste bo bedwaçunî  hokarekan bo 
eweî bizanirét ke boçî derencamekanî em twéjîneweye cîawaze le néwan hendék le le dayikbuwanî dereweî 
wilat be berawerd le gel le dayikbuwanî Swîd w le néwan ewanî ke pileî xwéndinyan nizimtire (herdu giropî 
le dayikbuwanî derewe w naweweî Swîd). 
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